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Investigating the role of ubiquitin in endosomal sorting and processing of 
amyloid precursor protein 
Rebecca Williamson 
Amyloid plaques, a neuropathological hallmark of Alzheimer’s disease (AD), are largely 
composed of amyloid beta (Aβ) peptide, derived from cleavage of amyloid precursor 
protein (APP) by β- and γ-secretase. The endosome is increasingly recognized as an 
important crossroads for APP and the secretases, with major implications for APP 
processing and amyloidogenesis. Amongst various posttranslational modifications 
affecting APP, ubiquitination of cytodomain lysines may represent a key signal 
controlling endosomal sorting. Here, we show that substitution of APP COOH-terminal 
lysines with arginines disrupts APP ubiquitination, though the pool of ubiquitinated APP 
is small or transient. Nonetheless, this small deficiency in ubiquitination can have a 
significant impact on APP, such that the number of lysines mutated trends toward an 
increase in APP metabolism. An APP mutant lacking all COOH-terminal lysines 
undergoes the most pronounced increase in processing, leading to accumulation of both 
secreted and intracellular Aβ40, without change in Aβ42. This phenotype is abolished by 
artificial ubiquitination of APP using rapalog-mediated proximity inducers. Lack of APP 
COOH-terminal lysines does not affect APP endocytosis, but leads to a redistribution of 
APP from endosomal intraluminal vesicles (ILVs) to the endosomal limiting membrane, 
with subsequent decrease in APP COOH-terminal fragment (CTF) content of secreted 
	
exosomes, but minimal effects on APP lysosomal degradation. Both the secreted and 
intracellular increase in Aβ40 is abolished by depletion of presenilin 2 (PSEN2), recently 
shown to be enriched on the endosomal limiting membrane compared to presenilin 1 
(PSEN1). In a separate set of studies, we found that a familial AD mutant, L723P, which 
occurs immediately next to a string of three lysines in the juxtamembrane region, behaves 
more similarly to other FAD-causing mutations. APP L723P exhibits a selective increase 
in Aβ42, and a delay in degradation, but no change in exosomal content, despite some 
missorting to the endosomal limiting membrane. Our findings demonstrate that ubiquitin 
can act as a signal for endosomal sorting at five lysines in the APP cytodomain, 
disruption of which prevents sequestration of APP in ILVs and results in the processing 
of a larger pool of APP-CTF by PSEN2 on the endosomal membrane.
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1 Chapter 1: Introduction 
1.1 Etiology of AD 
1.1.1 Clinical characteristics of AD 
Alzheimer’s disease (AD) is the most common cause of dementia, currently afflicting an 
estimated 5.4 million people in the United States, with an expected increase to 
approximately 13.8 million by 2050, as the population ages. The burden of AD, in terms 
of disability adjusted life years (DALYs) of patients, as well as lost productivity for 
unpaid caregivers, is increasing accordingly. In 2016 alone, the cost of healthcare for AD 
patients is estimated to be 236 billion dollars (2016 Alzheimer's disease facts and 
figures). AD is characterized clinically by a progressive cognitive decline, manifesting 
especially in episodes of confusion and loss of memory. Other cognitive functions 
become affected including decision-making, language, visuospatial orientation and 
abstract reasoning (Holtzman et al., 2011). Over time, patients become unable to care for 
themselves and eventually succumb to death, often from pneumonia or malnutrition. The 
typical duration of disease is 8-10 years, contributing to its staggering psychological and 
economic impact (2016 Alzheimer’s Disease Facts and Figures). 
The vast majority of all AD cases occur after the age of 65, and are termed late onset AD 
(LOAD) or sporadic AD. Early onset AD (EOAD) represents less than 5% of all AD 
cases in the United States (Bertram & Tanzi, 2012). One of the most challenging 
problems facing the field of AD research and therapeutics is the long prodromal phase of 
disease that occurs before AD clinical symptoms present. Amyloid pathology can 
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develop several decades before loss of memory occurs. In fact, the National Institute on 
Aging (NIA) revised diagnostic criteria for AD in 2011 to reflect this prodromal phase 
(Sperling et al., 2011). Diagnosis is accepted at an earlier stage of disease, known as mild 
cognitive impairment (MCI), which is defined as cognitive decline greater than expected 
for a patient’s age and education level, but not significantly interfering with everyday 
activities. About two thirds of patients with MCI will progress to dementia over 5 years, 
though it remains unclear why others remain cognitively stable or experience 
improvement (Sperling et al., 2011). In concert with effective therapeutics, identification 
of biomarkers that can reliably predict which patients will manifest AD pathology before 
symptoms become apparent, are in dire need. 
1.1.2 Pathological Characteristics of AD 
Along with a clinical diagnosis of AD, neuropathological examination of the brain at 
autopsy is necessary to fully differentiate AD from other causes of dementia. Diagnosis 
of AD requires the presence of two pathological features including amyloid plaques and 
neurofibrillary tangles (Figure 1.1). The main component of amyloid plaques is amyloid 
beta (Aβ) peptide, which is the product of cleavage of amyloid precursor protein (APP) 
by β- and γ-secretase. Neurofibrillary tangles (NFTs) are aggregates of 
hyperphosphorylated microtubule associated protein tau, though these are also 
pathological features of other disorders such as frontotemporal dementia and 
supranuclear palsy (Hyman et al., 2013). Although amyloid plaques and NFTs can also 
be identified in normal age-matched controls, they are typically more dense and widely 
spread in an AD brain, and can be staged based on the original criteria from Braak and 
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Braak (Braak & Braak, 1991). Braak staging is based on the extent and location of NFTs, 
which seem to correlate more closely with neuronal injury (Braak & Braak, 1991). The 
six stages have recently been combined into four stages, which can be briefly 
summarized as: Braak I/II with NFTs in entorhinal cortex and closely related areas, 
stages III/IV with more NFTs in hippocampus and amygdala and some association 
cortex, and stages V/VI with NFTs widely distributed throughout the neocortex, 
eventually involving primary motor and sensory areas (Hyman et al., 2013). Although 
amyloid pathology is apparent by definition, there is a greater diversity in amyloid 
deposits of the AD brain, including neuritic plaques, which contain dystrophic neurites 
surrounding an amyloid core, and diffuse plaques, the significance of which is unclear 
(Hyman et al., 2013). Neuritic plaques and NFTs correlate with clinical symptoms of AD, 
but the presence and contribution of other lesions must also be understood. Synapse loss, 
neuronal atrophy, gliosis, degeneration in white matter and protein aggregates generally 
associated with other diseases, such as Lewy bodies or TAR-DNA-binding protein (TDP-
43) reactive inclusions can be present together with AD pathology (Holtzman et al., 
2011). Identification and quantification of these neurological lesions in a living person 
has been one of many challenges facing the AD field, but research into biomarkers, both 
imaging and biochemical, is advancing quickly. 
The advent of brain amyloid imaging (BAI) using specialized positron emission 
tomography (PET) scans allowed diagnostics of amyloid burden that was previously 
attainable only via autopsy. Combining BAI and cerebrospinal fluid (CSF) biomarkers 
allows further classification of patients. “Asymptomatic cerebral amyloidosis” refers to a 
high BAI amyloid signal or low CSF Aβ42 level, while “presymptomatic AD” refers to a 
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patient with a high tau CSF level, and a high BAI amyloid signal or low CSF Aβ42 level 
(Gandy & DeKosky, 2013). Although these classification tools are useful to stratify 
patients and determine disease progression in clinical trials, it is important to remember 
that not all patients with a high amyloid burden via BAI will progress to AD. Recent 
advances in imaging tau pathology and white matter changes in preclinical AD offer 
more hope that imaging could aid in earlier diagnosis of disease, but these techniques are 
in initial stages and suffer from low specificity (Brosch et al., 2016; Dean et al., 2016). 
These new techniques allow us some insight into neuropathological changes in a living 
person, but in order to accurately predict disease progression, we must first understand 
the molecular mechanisms by which each factor contributes to disease, or results from it. 
The pathology that is characteristic in the AD brain was described decades ago, and has 
led to the prevailing theory that has driven much of the research and therapeutics in the 
field thus far – the amyloid cascade hypothesis.  
1.1.3 Amyloid cascade hypothesis 
Based on the discovery of APP as the parent protein of Aβ, purified from amyloid 
plaques in the brain vasculature and parenchyma (Glenner & Wong, 1984a; Kang et al., 
1987), and the genetic mutations in APP discovered in families with AD and Down 
Syndrome (DS) patients (Glenner & Wong, 1984b; Goate et al., 1991), the amyloid 
cascade hypothesis developed. That AD can be caused by a single mutation in the APP 
gene, or by a triplication of APP in the case of DS, led Hardy and Higgins to hypothesize 
that deposition of Aβ is the initial and precipitating factor in AD that leads to other 
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downstream events such as neurofibrillary tangles, synaptic dysfunction and neuronal 
atrophy (Figure 1.2) (Hardy & Higgins, 1992). 
The amyloid cascade hypothesis gained support from several lines of evidence. Firstly, 
additional AD autosomal dominant mutations were found in presenilin (PSEN)1 and 
PSEN2 involved in processing of APP (Levy-lahad et al., 1995; Sherrington et al., 1995). 
Mutations leading to EOAD in the APP, PSEN1 and PSEN2 genes generally increase the 
levels of Aβ production, or alter the ratio of Aβ species in favor of the more aggregate 
prone, C-terminal extended species (Borchelt et al., 1996, 1997; Duff et al., 1996; 
Scheuner et al., 1996). Furthermore, a mutation in APP that is protective against AD, 
A673T, both decreases levels of Aβ and renders the peptide less aggregate prone 
(Benilova et al., 2014; Jonsson et al., 2012; Maloney et al., 2014). These findings fulfill 
the first prediction of the amyloid cascade hypothesis, that other causes of AD (in this 
case, genetic cases of EOAD) alter amyloid levels. Secondly, mutations in the tau protein 
that aggregate to form neurofibrillary tangles do not cause AD, but instead lead to other 
types of dementia such as frontotemporal dementia (FTD) (Goedert, Crowther, & 
Spillantini, 1998; Li et al., 2015). Injection of Aβ fibrils into the brain of mice leads to 
tau phosphorylation and formation of intracellular neurofibrillary tangles (Götz et al., 
2001; Selkoe & Hardy, 2016). These and many other studies suggest that amyloid 
pathology induces tau pathology, and not vice versa. Twenty-five years after the 
hypothesis was formed, the evidence in favor of the amyloid cascade hypothesis seems 
convincing, however there are three main predictions that have yet to be fully realized.  
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The amyloid hypothesis would predict that (1) Aβ induces tau pathology, (2) Aβ is toxic 
to neurons and (3) eliminating Aβ and plaques in the brain would improve cognition and 
prevent AD progression. The relationship between amyloid and tau pathology continues 
to be a controversial topic in the field. The amyloid cascade hypothesis would predict that 
amyloid pathology predates and induces neurofibrillary tangles, and some data does 
suggest that this is true, as described above. However, even in the original staging of 
Alzheimer’s pathology, Braak and Braak noted areas of the brain that contained NFTs 
without evidence of amyloid deposition, and a stronger correlation between AD clinically 
and extent of NFT pathology (Braak & Braak, 1991). Numerous other studies have 
identified a stronger correlation of the cognitive and synaptic defects of AD to tau 
pathology than to amyloid plaques, but soluble Aβ aggregates are increasingly recognized 
as the toxic Aβ product (Hardy & Selkoe, 2016). Nevertheless, Aβ toxicity is tau 
dependent (Rapoport et. al., 2002) and crossing mutant tau transgenic mice with mutant 
FAD APP transgenic mice augments tau pathology (Lewis et al., 2001), while reduction 
of tau ameliorates cognitive and neuronal dysfunction induced by Aβ (Roberson et al., 
2007). Together, these studies suggest that tau pathology lies downstream of amyloid 
pathology, however, there remains much unknown regarding the link between the two.  
The second prediction, that Aβ mediates cytotoxic effects, can be fulfilled by the 
“oligomer hypothesis”, an adjustment to the amyloid hypothesis that identifies soluble 
Aβ oligomers as the culprit in AD, as opposed to amyloid plaques. Although the amyloid 
plaques are macroscopically visible and, by definition, present in all Alzheimer’s brains, 
evidence is growing that it is toxic Aβ oligomers that may be the pathogenic agent in AD. 
In fact, cognitive decline correlates with amyloid levels when measured via an oligomer-
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specific ELISA, lending more support to the notion that soluble amyloid species are more 
cytotoxic and that plaques represent a type of amyloid “sink” (Esparza et al., 2013). This 
concept is consistent with the observation that Aβ42 levels actually decrease in CSF of 
patients with late-stage AD, suggesting that Aβ42 becomes bound to plaques in the brain 
parenchyma (Blennow et al, 2015). Numerous studies have now shown that Aβ 
oligomers isolated from AD brains exert toxic effects such as decreased synapse density, 
diminished LTP, and enhanced LTD in rodents as well as tau hyperphosphorylation 
(Selkoe & Hardy, 2016). On the other hand, neuritic plaques are encircled by activated 
microglia that extend processes into the plaque core, indicating that deposited Aβ triggers 
an immune response, and that the amyloid plaque plays a role in precipitating 
characteristic inflammatory factors in AD (Mandrekar-Colucci & Landreth, 2010). 
The third prediction, that reducing Aβ or amyloid load in the brain would improve 
symptoms is perhaps the most disappointing “failure” of the amyloid hypothesis. Several 
clinical trials of drugs that reduce amyloid pathology, such as Aβ42 immunization 
studies, showed disease progression even in patients whose Aβ load was significantly 
reduced (Selkoe & Hardy, 2016). Supporters of the amyloid cascade hypothesis argue 
that interfering after symptoms have already presented is ineffective, because at that point 
disease pathology has been developing for years, if not decades. Of note, a more recent 
Phase II clinical trial of an antibody against N-terminal Aβ that specifically recognizes 
fibrillar Aβ, found both a dose-dependent reduction in amyloid deposition by PET scan 
and a dose-dependent slowing of cognitive decline (Sevigny et al., 2016). Confirmatory 
studies are necessary in a larger cohort Phase III clinical trial, but initial results buoy 
hope for amyloid-reducing therapeutics. A full review of support for or against the 
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amyloid cascade hypothesis is out of scope of this dissertation, but it is evident that 
understanding APP processing and the resultant fragments are of utmost importance in 
elucidating the pathophysiology of AD.   
1.1.4 Genetics of AD 
Genetically, AD can be separated into familial AD (FAD), with Mendelian inheritance 
that presents predominantly with EOAD, and sporadic AD with more complex genetic 
and environmental contributions that presents predominantly with LOAD. Most FAD 
cases occur due to mutations in one of three genes including APP, PSEN1, or PSEN2 
(Bertram & Tanzi, 2012). PSEN1 and PSEN2 are components of the γ-secretase 
complex, which function in the pathway of APP proteolysis and result in the release of 
Aβ peptide (Figure 1.3), which will be explored in depth in subsequent chapters.  
A link between AD and DS exists because the APP gene is on chromosome 21, and thus 
triplicated in DS patients. In fact, the discovery that Aβ was the main component of 
cerebrovascular plaques in both AD and DS led to the initial prediction by Glenner and 
Wong that an “Alzheimer’s gene” exists on chromosome 21 (Glenner & Wong, 1984b). 
From there, Kang et al. were able to identify the full length precursor protein, APP, and 
recognize that it shares similarities with other integral membrane glycoproteins (Kang et 
al., 1987). Several isoforms of APP exist through alternative splicing, though only three 
are present in the central nervous system: APP770, and APP751 which are also present in 
the peripheral nervous system and APP695 which is restricted only to the central nervous 
system and is the predominant form in neurons (Bekris et al., 2010; Kang & Müller-Hill, 
1990). Although the function of APP remains unknown, increasing evidence points 
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towards a role for APP in formation and maintenance of synapses (Nhan et al., 2016). 
Most autosomal dominant mutations of APP occur within the Aβ peptide sequence and/or 
around the sites of secretase cleavage and lead to an increase in levels of total Aβ by 
enhancing BACE1 (beta-site amyloid precursor protein cleaving enzyme 1) cleavage 
(e.g., Swedish mutation), favor the production of longer, more aggregated Aβ species by 
perturbing interaction with  γ-secretase (e.g., London mutation) or simply generates 
mutated Aβ peptides that are more prone to aggregation (e.g., Arctic mutation) (Bateman 
et al., 2011). 
The most commonly mutated gene in autosomal dominant EOAD is PSEN1, which also 
corresponds to the most aggressive form of disease with an earlier age of onset, though 
different mutations carry a wide range of phenotypic variability (Bekris et al., 2010). 
PSEN2 mutations are more rare, with only 20 known FAD mutations compared to the 
185 known PSEN1 mutations (Bekris et al., 2010). PSEN1 and PSEN2 encode for an 
aspartyl protease transmembrane protein, one of which is required to form the catalytic 
core of the γ-secretase complex, responsible for the final step of APP cleavage to release 
Aβ (De Strooper et al., 1998; Wolfe et al., 1999). In addition to APP, the γ-secretase 
complex cleaves other transmembrane proteins, including Notch, so it is not surprising 
that PSEN1 KO animals are embryonically lethal. Most of the PSEN1 mutations tend to 
decrease Aβ production, although they lead to an increase in the proportion of C-
terminally extended Aβ species, thus increasing the ratio of Aβ42/40 and favoring 
amyloid deposition (De Strooper, Iwatsubo, & Wolfe, 2012). Although FAD producing 
mutations in APP, PSEN1 and PSEN2 contribute only a small percentage of all AD cases, 
the clinical and pathological features are largely the same as in LOAD (Bateman et al., 
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2011). Thus, study of these mutations has been important in understanding this disease 
processes.  
The strongest known genetic link to LOAD is the apolipoprotein E4 (APOE4) variant. 
Three variants of APOE exist (APOE2, APOE3 or APOE4), and one copy of the APOE4 
variant increases risk of AD approximately 3 fold, while APOE4 homozygotes can carry 
a 12 fold greater risk (Liu et al., 2013). Humans and transgenic mice carrying the APOE4 
variant have a higher load of brain Aβ levels and amyloid plaques, and worse outcomes 
after traumatic brain injury and stroke (Liu et al., 2013). Although the mechanism of 
APOE4 risk in AD pathogenesis is not entirely understood, studies point to a role for 
APOE in amyloid deposition and clearance of Aβ, or underline the link between APOE 
as a regulator of cholesterol metabolism, which can be dysregulated in AD (Liu et al., 
2013). Another intriguing idea is that APOE has an Aβ-independent role in refining 
synaptic circuitry. Astrocytes contain most of the APOE in the brain, and variants of 
APOE have differential effects on phagocytic activity, such that APOE4 inhibits pruning 
of synapses more than APOE3 or APOE2 (Chung et al., 2016). It is clear that we still 
have much to learn regarding the role of APOE and the contribution of APOE4 to AD 
pathogenesis, including its interaction with Aβ pathology, 
More recently, advances in high throughput genome wide screens have allowed the field 
to identify additional genes with polymorphisms that may contribute to LOAD. These 
genome wide association studies (GWAS) identified several genetic “hits” that can be 
loosely grouped into functional pathways including: amyloid pathway, immune system 
and inflammation, lipid transport and metabolism, and endocytosis/endosomal vesicle 
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cycling (Table 1.1) (Dong et al., 2016). These groupings give us clues into the systems 
that may be disrupted in the pathogenesis of AD. Of note, several GWAS hits have a role 
in the endo-lysosomal system trafficking, including BIN1 (bridging integrator 1), 
PICALM (phosphatidylinositol binding clathrin assembly protein), CD2AP (CD2 
associated protein), and SORL1 (sortilin related receptor 1) (Rogaeva et al, 2007; 
Lambert et al, 2013), suggesting that this pathway might be affected in AD. It is 
important to recognize that many of the early GWAS were performed in non-Hispanic 
Whites of European ancestry, and that the loci of interest or contribution of genetic risk 
factors may differ for other populations. For example, in identification of the effect of 
ABCA7 risk, most of the effect sizes were small, with an odds ratio ranging from 1.16 to 
1.20. However, in a study of African Americans, the effect size of ABCA7 was much 
stronger, with an odds ratio of 1.79 (Reitz et al., 2013). With the inclusion of more 
groups into genetic studies, we may uncover additional genes involved in AD 
pathogenesis.  
1.1.5 Clinical trials of Aβ-reducing therapeutics 
The only FDA-approved AD drugs currently available are a handful of cholinesterase 
inhibitors that are relatively ineffective in halting disease progression. By contrast, the 
majority of AD therapies in development target Aβ production or amyloid plaques. 
Unfortunately, clinical trials aimed at lowering amyloid burden have been largely 
disappointing thus far. Although some may be tempted to abandon the amyloid cascade 
hypothesis in the face of such a result, there is much to learn about the reasons behind 
each failure. Several studies have used monoclonal antibodies to target amyloid and 
	 12	
promote its clearance. Bapineuzumab binds amyloid plaques and has been effective in 
preclinical models, however, infusion in humans led to cerebral edema without any 
clinical effect on amyloid load (Salloway et al., 2014). Another antibody, solanezumab, 
binds to soluble Aβ and showed some cognitive improvement in a subgroup of patients 
that had milder AD, but a recent announcement from a Phase III trial failed to 
significantly slow cognitive decline (Doody et al., 2014). It could be that this type of 
amyloid clearing treatment is only effective at earlier stages, before extensive pathology 
develops. This is the hope for aducanumab, discussed above, currently in Phase III trials 
in patients with mild AD (Sevigny et al., 2016).  
To determine whether therapies have an effect at an earlier, pre-symptomatic phase of 
AD, researchers turn to cohorts of patients carrying autosomal dominant FAD mutations. 
The Dominantly Inherited Alzheimer Network (DIAN) gathers together carriers of 
autosomal dominant AD mutations and their non-carrier siblings, in order to study a 
population of people who are expected to progress to AD. The purpose is to identify 
positive biomarkers before symptoms present, and to administer therapeutics at a pre-
symptomatic phase to prevent development of pathology (Bateman et al., 2012). A 
similar trial in a large cohort carrying a PSEN1 FAD mutation in Colombia has similar 
goals of targeting therapies to a high-risk population at a pre-symptomatic stage (Reiman 
et al., 2011). The applicability of these studies to the vast majority of AD patients with 
sporadic disease assumes that the pathogenesis is similar between EOAD and LOAD, 
which is not entirely understood.  
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Another option to quell the formation of Aβ pathology is to modulate its production by 
inhibiting the secretases that cleave APP into Aβ. As the rate-limiting step in the 
amyloidogenic pathway, BACE1 is an attractive candidate for therapeutics. Moreover, 
carriers with only one copy of the protective A673T mutation that disfavors BACE1 
cleavage have only a modest reduction in Aβ of ~20%, but are still protected against AD 
(Jonsson et al., 2012). This provides proof of principle that β-secretase inhibitors could 
successfully ward off AD, and that only a fairly small lowering of Aβ is necessary. 
BACE1 -/- mice have a wide range of subtle phenotypes, attributed to dysregulation of 
BACE1 substrates, such as neuregulin 1 (Vassar, 2014). These toxicities are of concern 
for a therapy that would need to be taken for decades for effective AD prevention. 
However, it is not clear how much these phenotypes reflect developmental versus adult 
deficiencies. Recent studies of inducible knockout mice that experience loss of BACE1 in 
adulthood are promising in that many of the BACE1 knockout phenotypes are avoided, 
suggesting that the phenotypes are due to lack of BACE1 in developmental stages 
(Alzforum news, unpublished data). However, the mice may have some defects in 
memory acquisition, and the studies are still underway. In the meantime, BACE1 
inhibitors continue to be developed and tested for clinical use. Early inhibitors were 
peptide-based and possessed poor pharmacokinetics, including low blood brain barrier 
permeability (Vassar, 2014). Small molecular BACE1 inhibitors, such as LY2886721, 
have improved characteristics, but suffer from side-effects in clinical trials unrelated to 
BACE1 inhibition (Vassar, 2014). Another small molecular inhibitor, verubecestat (MK-
8931), has been more successful in recent reports showing a decrease in CSF levels of 
Aβ40, Aβ42, and sAPPβ in animal models and in both cognitively normal and AD 
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patients, without commonly associated side effects of BACE1 inhibition (Kennedy et al., 
2016). Verubecestat and other BACE1 inhibitors currently undergoing early clinical trials 
provide a promising direction for BACE1 inhibitors as effective AD prevention.  
Trials of γ-secretase inhibitors have been largely ineffective due to intolerable side effects 
associated with Notch inhibition. One such drug, semagacestat, actually increased 
cognitive decline in certain measures of cognition at the highest dose of treatment 
(Doody et al., 2013). Other trials of Notch-sparing γ-secretase inhibitors still carry 
concern for Notch-related side effects (De Strooper & Gutiérrez, 2015). Gamma-
secretase modulators, which skew the cleavage of γ-secretase complex towards shorter 
and less-aggregate prone species of Aβ, are still a promising arena for new therapeutics. 
A subset of non-steroidal anti-inflammatory drugs (NSAIDs) were shown to specifically 
decrease production of Aβ42 and increase Aβ38, without significantly affecting cleavage 
of Notch (Golde et al., 2013). Tarenflurbil, an early NSAID based γ-secretase modulator, 
showed no improvement in cognition in a Phase III study, likely due to inefficient CNS 
penetrance (Golde et al., 2013). Newer compounds, such as CHF5074 are currently in 
Phase II trials (Golde et al., 2013). An important question regarding γ-secretase 
modulators is whether increasing the ratio of smaller Aβ species is able to interrupt 
amyloid aggregation once Aβ42 has triggered nucleation. This could have important 
implications for treatment initiation, and whether γ-secretase modulators will function 
better as prophylaxis or treatment. Furthermore, the contribution of shorter species of Aβ 
to amyloid pathology remains largely unknown.  
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Another therapeutic possibility includes targeting specific γ-secretase complexes, with 
the presumption that different configurations of γ-secretase components PSEN1/2 or 
APH-1A/B have different functions within the cell. Evidence suggests that PSEN1-
containing γ-secretase complexes are responsible for Notch cleavage, and that specific 
inhibition of PSEN1 would be an effective AD therapy. In fact, a sulfonamide based γ-
secretase inhibitor, MRK-560, displays 30-fold higher activity for PSEN1 than PSEN2, 
and caused few Notch-related side-effects in mice (Best et al., 2006). APH-1B deletion in 
mouse models of AD have been shown to improve cognition and reduce amyloid 
pathology without an effect on Notch, suggesting that inhibition of this γ-secretase 
component would also be an effective therapy (Acx et al., 2013; Serneels et al., 2009). 
The role and specificity of different γ-secretase complexes is a relatively understudied 
subject in the field of AD, and will be vital to the understanding and development of new, 
more specific therapeutic compounds.  
 
1.2 APP trafficking and processing 
APP, α-, β-, and γ-secretase are all integral membrane proteins (or protein complexes), 
underlining the importance of their trafficking along intracellular membranes. A simple 
notion is that the trafficking pattern of APP and its secretases, particularly the "co-
residence time" on given organelles, has a profound impact on APP processing (Figure 
1.4). The canonical α-, β- and γ-secretase processing of APP has been extensively studied 
in the past two decades and will be discussed in detail below. Additional pathways of 
APP cleavage have been identified recently, though the significance of each has yet to be 
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explored, particularly in vivo. Asparagine endopeptidase (AEP), termed δ-secretase, 
cleaves APP at two sites in the ectodomain (Zhang et al., 2015), while matrix 
metalloproteinase MT5 (MT5-MMP) cleaves APP in the N-terminal domain, termed η-
secretase, to release cytotoxic fragments (Willem et al., 2015). Here, we will discuss the 
canonical α-, β-, and γ-secretase pathways of APP processing. 
1.2.1 α-secretase processing of APP 
The 37-43 amino acid Aβ is formed by sequential cleavage of APP by β- and γ-secretases 
(Figure 1.3) (Haass et al., 2012). APP is a type 1 transmembrane protein with a large 
ectodomain and shorter COOH-terminus that extends into the cytosol (Kang et al., 1987). 
APP is synthesized in the ER, then transported to the Golgi and trans-Golgi network 
(TGN) where it undergoes glycosylation, phosphorylation and sulfation to its mature 
form (Haass et al., 2012). Like other type 1 transmembrane proteins, APP is transported 
to the plasma membrane via the secretory pathway, where it is processed primarily by α-
secretase in the non-amyloidogenic pathway (Rajendran & Annaert, 2012). Alpha-
secretase cleavage is mediated by several zinc metalloproteinases, the most 
physiologically relevant for constitutive cleavage being a disintegrin and 
metalloproteinase 10 (ADAM10) (Kuhn et al., 2010). This pathway is known as non-
amyloidogenic because α-secretase cleavage occurs within the Aβ domain of APP, 
precluding generation of the intact Aβ peptide. Instead, α-secretase leads to release of a 
membrane soluble fragment known as sAPPα, and the membrane bound COOH terminal 
fragment C83 (or CTFα). The latter can then be cleaved by γ-secretase to release the p3 
fragment, which is relatively understudied, but may mediate harmful effects based on the 
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fact that it contains the amino acids necessary for toxicity in Aβ (Nhan et al., 2016). 
Conversely, sAPPα has been ascribed neuroprotective functions, especially in 
development and promotion of neurite outgrowth (Nhan et al., 2016).  
1.2.2 BACE1 processing of APP 
In the amyloidogenic pathway, APP is initially cleaved by BACE1 (Rajendran & 
Annaert, 2012). BACE1 is transported to the endosome via endocytosis from the plasma 
membrane, or direct translocation from the Golgi complex, followed by transport to the 
recycling endosome. BACE1 cleavage of APP releases the soluble ectodomain of APP 
(sAPPβ) luminally and the membrane-bound COOH-terminal fragment C99 (or CTFβ) 
(Rajendran & Annaert 2012). The C99 fragment has been ascribed toxic attributes, 
especially as contributing to endocytosis defects that occur in AD (Cataldo et al., 2000; 
Jiang et al., 2010, 2016; Woodruff et al., 2016). BACE1 can also cleave APP further 
downstream to produce a smaller membrane bound fragment known as C89, leading to 
the corresponding Aβ11-40/42 (Haass et al., 2012).  
Several lines of evidence suggest that endosomes are the main sites of Aβ generation. 
First, BACE1 has an optimum pH of 4.5, which is consistent with BACE1 cleavage of 
APP occurring in lower pH of endosomes and lysosomes (Vassar et al., 1999). From the 
plasma membrane, APP is rapidly endocytosed in a clathrin-dependent manner via its 
YENPTY motif, disruption of which can decrease Aβ generation (Cirrito et al., 2008). 
BACE1 inhibitor specifically targeted to endosomal membranes reduced BACE1 activity 
more than soluble inhibitor (Rajendran et al., 2008). Some discrepancy remains regarding 
the endosomal compartment in which BACE1 cleavage of APP takes place. Sannerud et 
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al. showed that APP and BACE1 are endocytosed in distinct pathways, by clathrin and 
Arf6 (ADP-ribosylation factor 6), respectively, before converging in the early endosome 
(Sannerud et al., 2011). Das et al. used live-imaging studies in neurons to determine that 
APP and BACE1 converge upon neuronal activity in a clathrin-dependent manner and 
that recycling endosomes are the main sites of their convergence (Das et al., 2013, 2016). 
Although much evidence implicates the endosomal pathway as the site of BACE1 
cleavage, some discrepancies exist that may be due to differences in fixed versus live 
cells and in use of non-neuronal cell types. Resolving these controversies to uncover the 
intracellular itineraries of APP and BACE1 will be essential in our understanding of Aβ 
generation. 
1.2.3 APP and the γ-secretase complex 
After BACE1 processing, the C99 fragment is cleaved within the transmembrane domain 
by γ-secretase, releasing Aβ and APP intracellular domain (AICD). The cytosolic AICD 
is produced by γ-secretase cleavage of both C83 and C99, and translocates to the nucleus 
where it has been proposed to function as a transcription factor (Nhan et al., 2016). 
Gamma-secretase cleaves C99 in a sequential fashion, releasing multiple Aβ peptides of 
different lengths (Qi-Takahara et al., 2005; Wolfe, 2012). Of these, the most abundant is 
Aβ40, while longer peptides, such as Aβ42 and Aβ43, are more prone to aggregation and 
generally more synapto- and neurotoxic (Saito et al., 2011). In familial AD (FAD), 
overall levels of Aβ increase, or there is a shift in Aβ production that increases the ratio 
of Aβ42/40 (De Strooper et al., 2012). However, in the majority of AD cases, which 
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occur sporadically as LOAD, mechanisms of Aβ accumulation remain poorly understood, 
although they likely also involve reduced Aβ clearance.   
The four components of the γ-secretase complex were discovered over the course of 10 
years, beginning with the discovery that familial missense mutations in PSEN1 and 
PSEN2 lead to EOAD and that PSEN is essential for the production of Aβ peptides (De 
Strooper et al., 1998; Duff et al., 1996; Levy-lahad et al., 1995; Sherrington et al., 1995; 
Wolfe et al., 1999). Other components of the γ-secretase complex were identified by co-
immunoprecipitation of presenilin or through screens of Notch modifiers (De Strooper et 
al., 2012). The four proteins, nicastrin, anterior pharynx-defective phenotype (APH-1), 
presenilin enhancer (PEN-2), and PSEN combine in a 1:1:1:1 stoichiometry to form the 
complete γ-secretase complex. Mutagenesis of two aspartyl residues in the 
transmembrane domain of PSEN1 led to a dominant negative effect of γ-secretase, 
suggesting that presenilin is in fact the catalytic subunit of the complex (Wolfe 1996b). 
The two homologous proteins, PSEN1 and PSEN2, are both synthesized as a 50kDa 
precursor that is then cleaved into a 30kDa N-terminal fragment and a 20kDa C-terminal 
fragment that form a nine-transmembrane domain protein (Laudon et al., 2005; Spasic et 
al., 2006; Thinakaran et al., 1997). Gamma-secretase cleaves APP in multiple steps, first 
at the ε-site that releases AICD 50-99 or a minor species 51-99. The resulting long Aβ 
peptide remains in the active site and undergoes processive γ-cleavage every 3-4 residues 
to release Aβ species in two pathways: Aβ49à Aβ46à Aβ43à Aβ40 and Aβ48à 
Aβ45à Aβ42à Aβ38 (Wolfe, 2012).  
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The γ-secretase complex assembly begins in the ER before transport of fully formed 
tetramers to the Golgi complex, however, it is unclear exactly how complexes assemble 
(Rajendran and Annaert, 2012). Most PSEN1 in the cell is found in the biosynthetic 
pathway, but it is not part of active complex (Annaert et al., 1999; Kaether et al., 2006; 
Réchards et al., 2003). Only a small percentage of PSEN1 exists in fully-formed, active 
complexes that can cleave substrates in post-Golgi compartments. At least two γ-
secretase subunits, nicastrin and Aph-1A, have ER retention motifs that are masked upon 
assembly of the complex, and Golgi-induced post-translational modifications may also 
play a role in transport to subsequent compartments (Rajendran & Annaert, 2012). It is 
not entirely clear where γ-secretase cleavage of APP-CTFs normally takes place, but 
post-Golgi PSEN1 and nicastrin is mainly localized at the cell surface and in the endo-
lysosomal pathway (Kaether et al., 2004; Pasternak et al., 2003; Réchards et al., 2003). 
BACE1 and γ-secretase components can localize to specific microdomains in the 
membrane, known as lipid rafts, via palmitoylation, which might preferentially cleave 
APP in the amyloidogenic pathway (Rajendran & Annaert, 2012). The contribution of 
different γ-secretase components to complex localization (either in membrane 
microdomains or cellular compartments) is only just being investigated, and may have 
significant impacts on substrate specificity or cleavage. 
 
1.3 APP in the endosomal pathway 
Endosomal dysfunction has long been recognized as a feature of AD (Cataldo et al., 
2000, 2004; Ginsberg et al., 2010; Nixon, 2005). The early endosome is a site of 
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transmembrane protein cargo sorting. The endo-lysosomal pathway maintains the identity 
of distinct compartments via specific Rab GTPase signatures. The early endosome is a 
significant point of transmembrane protein sorting, where cargos can be sorted to the 
retromer, the recycling pathway or into multivesicular endosomes (MVEs). MVEs are 
formed via invagination of the endosomal membrane that pinches off to form ILVs. 
Protein cargo sorted into the ILVs is destined for lysosomal degradation or release as 
exosomes (Figure 1.5). Understanding how APP traffics through the endosomal pathway, 
and the signals regulating its transport, is crucial to our knowledge of APP processing. 
Some endosomal sorting pathways that recognize and transport APP can modulate Aβ 
production and have been implicated in AD. One of the most well-studied is the retromer, 
which is a complex of proteins that retrieve endosomal cargo for transport back to the 
TGN or to the plasma membrane (Small & Petsko, 2015). Two core retromer 
components, vacuolar protein sorting (VPS)26 and VPS35, were found to be deficient in 
the entorhinal cortex, a vulnerable brain region in patients with AD (Small et al., 2005). 
As mentioned above, SORL1 (sortilin-related receptor 1) was identified as a “hit” in 
GWAS of LOAD patients (Rogaeva et al., 2007), and is a retromer receptor that can bind 
to APP (Small & Petsko, 2015). Retromer deficiency contributes to AD pathogenesis by 
increasing the residence time of APP on the endosomal membrane, thus promoting APP 
processing into Aβ (Bhalla et al., 2012; Muhammad et al., 2008). Agents that stabilize 
retromer components are now being explored as therapeutics for AD, to limit APP 
processing (Mecozzi et al., 2014). Clearly, the regulation of endosomal sorting pathways 
has implications for APP processing and amyloidogenesis. Here, we will discuss further 
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the mechanisms of MVE biogenesis and downstream trafficking events as they relate to 
APP.  
1.3.1 APP sorting in multivesicular endosomes 
Aβ is secreted from the neuron in normal metabolism, however, early in the pathogenesis 
of AD it accumulates intraneuronally in MVEs with toxic effects (Takahashi et al., 2002, 
2004). MVEs are formed from the invagination of the endosomal membrane into the 
lumen of the endosome, creating two or more ILVs. The endosomal pathway is clearly an 
important site for APP metabolic dysfunction, and elucidating the mechanisms of APP 
endosomal sorting will be critical to our understanding of AD pathogenesis. ILV 
biogenesis is a cellular feat that is topologically distinct from other membrane 
deformation events, such as endocytosis, because it requires budding and pinching off 
away from the cytosol. Many of the components that govern this process were originally 
discovered in yeast studies of VPS mutants (Raymond et al., 1992). The endosomal 
sorting complex required for transport (ESCRT) contains many of these highly conserved 
Class E VPS proteins that sort ubiquitinated cargo from the endosomal membrane into 
ILVs. 
ESCRT is actually a series of four proteins complexes (ESCRT-0, -I, -II, -III) that 
function sequentially to recognize ubiquitinated cargo in the endosome, deform the 
endosomal membrane and pinch off ILVs (Figure 1.6) (Raiborg & Stenmark, 2009). 
ESCRT-0 is composed of hepatocyte growth factor-regulated tyrosine kinase substrate 
(Hrs) and signal transducing adaptor molecule (STAM), which are recruited to the 
endosomal membrane by a FYVE (Fab-1, YGL023, Vps27, and EEA1) domain in Hrs 
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that binds the endosomal lipid phosphatidylinositol-3-phophate (PI3P) (Raiborg et al., 
2001). Our lab found PI3P to be deficient in AD, which led to identification of APP as a 
cargo of the ESCRT pathway (Morel et al., 2013). Others have also identified an 
association between APP and ESCRT, such that depleting the cells of ESCRT 
components can modulate Aβ generation (Choy et al., 2012; Edgar et al., 2015). 
Recognition by ESCRT-0 is also necessary for protein sequestration, to prevent sorting to 
other endosomal pathways such as the retromer or recycling pathway. Thus, interruption 
of the normal ESCRT function could alter APP metabolism, by shunting APP to other 
endosomal sorting pathways, or causing accumulation of APP on the endosomal 
membrane (discussed in depth in subsequent chapters).   
Aside from ESCRT, there are other ubiquitin-independent pathways for ILV formation. 
Proteins can associate with lipid rafts, cluster in oligomers, or sort into ceramide 
microdomains to undergo sorting into ILVs (Colombo et al., 2014). It is tempting to think 
that different means of sorting could dictate the fate of the newly formed ILVs, though 
the mechanisms underlying downstream ILV pathways are largely uncharted. MVEs can 
be generally separated into two types, secretory MVEs (sMVE) or degradative MVEs 
(dMVE). These distinctions dictate whether the enclosed ILVs will be released into the 
extracellular space upon fusion of the sMVE with the plasma membrane, or degraded 
upon fusion of the dMVE with the lysosome. However, it is not yet known which factors 
contribute to the formation of an sMVE or dMVE (Budnik et. al., 2016). A portion of 
APP is degraded in lysosomes, and APP metabolites can be found in exosomes, therefore 
presence of APP in both sMVEs and dMVE is probable (Rajendran & Annaert, 2012).  
	 24	
1.3.2 Lysosomal degradation of APP 
The lysosomal system is a vesicular compartment with an internal pH of 3.5-6.0, and 
contains enzymes capable of degrading cellular components. Early studies of APP 
trafficking identified a significant amount of full-length APP that is degraded in the 
lysosome (Caporaso et al., 1992, 1994; Golde et al., 1992; Haass et al., 1992). Lysosomal 
dysfunction has been proposed as a factor in the pathogenesis of AD (Peric & Annaert, 
2015). ESCRT provides a link between the endo-lysosomal system and macroautophagy, 
a mechanism of cellular homeostasis where cytoplasmic targets or organelles are 
engulfed by autophagic membranes and delivered to lysosomes for degradation. 
Autophagosomes fuse with late endosomes or lysosomes via ESCRT machinery (Rusten 
& Stenmark, 2009). In AD, autophagic vacuoles accumulate inside of dystrophic neurites 
that surround amyloid plaques, suggesting that macroautophagy has some role or 
consequence in disease (Nixon et al., 2005). Paradoxically, autophagic vacuoles have 
been shown to be both a site of amyloidogenic cleavage and a site for Aβ clearance, 
though others have contested the role of macroautophagy in APP processing (Boland et 
al., 2010; Khandelwal et al., 2011; Yu et al., 2005). Also, non-catalytic roles of PSEN 
such as lysosomal acidification or calcium regulation can lead to lysosomal dysfunction 
in certain PSEN FAD mutations, or PSEN deficiency, though these results are 
controversial (Coen et al., 2012; Lee et al., 2010; Zhang et al., 2012). Finally, 
neurodegenerative aspects of the lysosomal storage disorder, Niemann-Pick disease 
(NPC), resemble AD pathology and levels of APP and its metabolites are increased in 
NPC mouse models (Peric & Annaert, 2015). Strategies for upregulation of lysosomal 
function, such as induction of TFEB (transcription factor EB, a master regulator of 
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lysosomal pathways), or genetic deletion of cystatin B (an inhibitor of lysosomal cysteine 
proteases), clear Aβ and reduce amyloid plaques in transgenic FAD mouse models (Xiao 
et al., 2015; Yang et al., 2011). Others have also shown beneficial effects of modulating 
lysosomal regulators or enzymes, underlining the importance of this pathway in the 
pathogenesis of AD (Peric & Annaert, 2015). 
1.3.3 APP metabolites in exosomes 
As an alternative to lysosomal degradation, ILVs can be released as exosomes. Exosomes 
are small vesicles that are secreted by nearly every cell type via the fusion of MVEs with 
the plasma membrane, liberating ILVs extracellulary. The ESCRT machinery is linked to 
exosome biogenesis, and silencing certain components of ESCRT or associated proteins 
can decrease exosome secretion (Colombo et al., 2013). Exosomes can be distinguished 
from other extracellular vesicles by their small size, 30-100nM, and markers that also 
reflect ESCRT biogenesis, such as alix and tumor susceptibility 101 (TSG101) (Colombo 
et al., 2014). Exosomes are increasingly recognized as important mediators of 
intercellular communication, and they can carry cellular components that cannot cross the 
plasma membrane, such as proteins, mRNA or non-coding RNAs. Exosomes can be 
isolated from various biological fluids, including blood and CSF (Coleman & Hill, 2015). 
Exosomes can contain proteins specific to their cell of origin, and as such have been 
explored as a source of biomarkers. Since exosomes can be taken up by cells, they have 
also been investigated as a device for delivery of therapeutics. For instance, exosomes 
loaded with BACE1 miRNA and targeted to neurons, microglia and oligodendrocytes 
were able to reduce BACE1 levels in the brain (Alvarez-Erviti et al., 2011). 
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The first hint that Aβ might be present in exosomes came from a study that showed 
accumulation of the peptide within MVEs (Takahashi et al., 2002). Subsequently, 
Rajendran et al. showed the presence of Aβ associated with exosomes isolated from the 
brains of AD patients (Rajendran et al., 2006). Due to the topology of ILVs and 
exosomes, the Aβ is bound to the exosomal membrane, but not found within the lumen of 
exosomes. APP and its metabolite, APP-CTF, are also found in exosomes (Perez-
Gonzalez et al., 2012; Vingtdeux et al., 2007). Additionally, tau is present in exosomes, 
and some evidence suggests that exosomes may be a mediator of pathological spread of 
tau in the AD brain (Malm et al., 2016). Our knowledge of the function and biogenesis of 
exosomes is still at the beginning stages, but it seems clear that they have potential for 
intercellular communication, and could be harnessed for therapeutics. Understanding the 
mechanisms by which protein and other cargos are sorted into ILVs is the first step to 
appreciating exosomal function. 
 
1.4 Ubiquitin-mediated endosomal trafficking 
Ubiquitination was first recognized as part of the ubiquitin-proteasome system for 
degradation of cytosolic proteins, but the landscape of ubiquitin-mediated cellular events 
that we appreciate now is decidedly more complex. Ubiquitin modification can regulate 
functions as diverse as DNA repair, mitophagy, and protein trafficking. Ubiquitin is a 76 
amino acid peptide that can be conjugated to other proteins as a signal for various cell 
fates. Through a series of enzymatic reactions, an isopeptide bond forms between 
ubiquitin and a ε-amino group of a lysine residue on the targeted protein (Tanno & 
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Komada, 2013). Ubiquitin is first recognized by the E1 ubiquitin-activating enzyme, then 
is passed to the ubiquitin conjugated E2 enzyme, and finally is conjugated to the target 
protein via the E3 ubiquitin ligase, which confers specificity to the reaction. We will 
mainly discuss the role of ubiquitin in transmembrane protein trafficking, and how it 
relates to APP and associated proteins. 
1.4.1 The polyubiquitin code 
The signaling potential of ubiquitin becomes more complex by the formation of 
polyubiquitin chains, whereby ubiquitin is conjugated to itself on one of its seven lysine 
residues (K6, K11, K27, K29, K33, K48, K63). Depending on the location of the 
ubiquitin chain elongation, the fate of the targeted protein may differ (Haglund & Dikic, 
2012; Tanno & Komada, 2013) (Figure 1.7). The best established ubiquitin signal is K48 
polyubiquitination of cytosolic proteins, which signal degradation via the proteasome. 
However, integral membrane proteins require a different signal because they are not 
accessible by the proteasome in the cytosol. Evidence suggests that membrane protein 
trafficking and degradation is regulated by monoubiquitination and K63 
polyubiquitination, though there is still a gap in our understanding of these chain types, as 
well as the less abundant polyubiquitin chains (Tanno & Komada, 2013). Initial studies in 
S. cerevisiae recognized ubiquitin as a signal for endocytosis and endosomal trafficking. 
In particular, monoubiquitination was sufficient for endocytosis of certain plasma 
membrane receptors, but K63 polyubiquitination was necessary for maximal efficiency 
(MacGurn et al., 2012). Ubiquitin can regulate other transmembrane protein trafficking 
events in the secretory pathway such as ERAD and exocytosis, in addition to endocytosis 
	 28	
and endosomal sorting (Figure 1.8) (MacGurn et al., 2012). Since APP has been 
implicated as a cargo of ESCRT, we focus our attention on the role of ubiquitin in the 
ESCRT pathway.  
Ubiquitinated cargo was initially identified to be the preferred substrate for binding by 
ESCRT-0, a complex of two proteins, Hrs and STAM, that both contain multiple 
ubiquitin interacting motifs (UIM). ESCRT-0 also clusters the cargo together and 
prevents it from being trafficked along other endosomal pathways. The ubiquitinated 
cargo is then passed to ESCRT-I via TSG101, and ubiquitin may be important for passing 
protein cargo through the correct ESCRT complex sequence. There has been some 
controversy regarding the preferred chain type of ubiquitin for ESCRT recognition. 
Monoubiquitination appears to be sufficient for recognition, but Hrs has been shown to 
have bind more strongly to polyubiquitination and to have a preference for K63 
polyubiquitin chains over K48 chains (Barriere et al., 2007; Lauwers et al., 2009; Stringer 
& Piper, 2011). Alix (apoptosis-linked gene 2-interacting protein X), an accessory 
component of ESCRT-III also binds to ubiquitinated proteins with a K63 polyubiquitin 
preference (Dowlatshahi et al., 2012). Before ILV formation is complete, the ESCRT 
machinery is deubiquitinated and recycled via the action of deubiquitinase Doa4 (in 
yeast) and AAA ATPase Vps4, respectively (Raiborg & Stenmark, 2009). Ubiquitin is a 
tightly regulated component of the ESCRT pathway. Thus, as a cargo of ESCRT, APP 
should be ubiquitinated in its COOH-terminal domain.  
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1.4.2 Ubiquitination of APP 
APP contains 5 C-terminal lysines that couple potentially be ubiquitinated: K724, K725, 
K726, K751, and K763. Two studies identified APP in screens of the ubiquitome. Kim et 
al. showed ubiquitination of APP K751 and K763 in a screen of HCT116 cell after 
proteasomal inhibition with bortezemib, and affinity purification using an antibody that 
recognizes the di-glycine remnant of ubiquitinated proteins (Kim et al., 2011). Similarly, 
Wagner et al. identified ubiquitination of APP K751 and K763 in a screen of the 
ubiquitome in unperturbed HEK293T cells (Wagner et al., 2011). Several studies have 
looked specifically at APP ubiquitination. El Ayadi et al. showed that ubiquilin-1 induces 
APP ubiquitination at K763 to sequester APP in the Golgi and prevent maturation (El 
Ayadi et al., 2012). Ubiquilin-1 negatively correlates with BRAAK staging in AD brains 
(El Ayadi et. al., 2013). Ubiquilin-1 is not an E3 ligase itself, but is a member of family 
of proteins that contain Ub-like domains (UBL) and Ub-associated domains (UBD), 
which could aid in transfer of ubiquitinated substrates such as in the recruitment of a E3 
ligase to APP. El Ayadi et al. show ubiquilin-1 slows degradation of APP, but do not 
specifically test its impact on APP metabolism.  
Bustamante et al. studied the role of APP ubiquitination in endoplasmic reticulum 
associated degradation (ERAD) and showed that expression of a C99 mutant, with all 
five C-terminal lysines substituted to arginine (C99-5KR), is not degraded as efficiently 
as wild-type C99 in a 0-30 minute time frame. C99-5KR accumulates in Golgi-like 
structures, potentially due to a deficiency in ERAD (Bustamante et al., 2013). While El 
Ayadi et al. indicate that ubiquitination leads to Golgi sequestration, Bustamante et al. 
	 30	
suggest that lack of ubiquitination of C99 causes the same fate. Thus the role of APP 
ubiquitination in the secretory pathway remains unclear.  
Only two potential E3 ubiquitin ligases have been discovered thus far: FBL2 and CRL4-
CRBN. FBL2 is a component of the Skp1-Cullin1-F-box protein (SCF) E3 ligase 
complex, and mRNA levels were shown by microarray to be depleted in the brains of AD 
patients, compared to controls (Blalock et al., 2004). Watanabe et al. showed that FBL2 
interacts with APP via co-immunoprecipitation and that overexpression of FBL2 induced 
APP ubiquitination at K726, and led to a reduction in Aβ40 and Aβ42 (Watanabe et. al., 
2012). However, they use APP lysine-to-alanine mutations, which do not maintain the 
positive charge at the residue, shown to be important for γ-secretase binding (Xu et al., 
2016). Furthermore, Watanabe et al. hypothesize that FBL2-induced ubiquitination leads 
to degradation of APP via the proteasome, which is not known to translocate 
transmembrane proteins for degradation. In a screen of interactors with the APP cytosolic 
region, Del Prete et al. identified a number of components of ubiquitin processing 
machinery including several E3 ubiquitin ligases and deubiquitinases and showed that all 
five C-terminal lysines were ubiquitinated (Del Prete et. al., 2016). CRL4-CRBN and 
Stub1 were the two most abundant E3 ligases in the pull-down, and CRL4-CRBN was 
shown to induce ubiquitination of K751 in vitro, and CRBN KO mouse brains to be 
deficient specifically in K751 ubiquitination in vivo (Del Prete et al., 2016). More work 
will need to be done to determine whether these E3 ligases can modulate APP 
metabolism and Aβ generation. 
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In our previous work, we showed that endogenous APP from mouse brain is 
ubiquitinated. We identified a string of three juxtamembrane lysines in the APP C-
terminal domain, mutation of which leads to a deficiency of APP ubiquitination in HeLa 
cells with subsequent redistribution of APP to the limiting membrane of the endosome 
(Morel et al., 2013). We hypothesized that the ubiquitin deficiency can disrupt 
recognition of APP by the ESCRT machinery. The contribution of other C-terminal APP 
lysines and the downstream effects of ubiquitin deficiency will be discussed in 
subsequent chapters. 
1.4.3 Ubiquitination of APP processing machinery 
BACE1 and components of the γ-secretase complex can also be ubiquitinated. Gamma-
secretase ubiquitination has been studied in the context of the ubiquitin-proteasome 
system, as opposed to cellular trafficking, although some evidence suggests that ubiquilin 
and the proteasome are responsible for presenilin endoproteolysis (Ford & Monteiro, 
2007; Massey et al., 2004). BACE1 is also ubiquitinated at a single lysine in the C-
terminus, leading to accumulation of BACE1 in endosomes and an increase in APP 
processing (Kang et al., 2012). Aβ levels can be reduced by depletion of deubiquitinase 
ubiquitin-specific protease 8 (USP8), which increases BACE1 ubiquitination and leads to 
a redistribution of BACE1 away from Rab11-positive recycling endosomes where APP 
cleavage is thought to take place (Yeates & Tesco, 2016). These studies underline the 
effect that ubiquitin regulators can have on Aβ production and the need for identification 
of ubiquitin ligases and deubiquitinases affecting APP itself.
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1.5 Figures 
Figure 1.1. Neuropathological characteristics of Alzheimer’s disease.  
Brain sections from an AD patient stained with silver. (a) Arrows point to neuritic 
plaques. (b) Intraneuronal neurofibrillary tangles. (c) An Aβ plaque showing amyloid 
(stained red with anti-Aβ antibody) and invading microglia  (stained green with anti-
IBA1). Scale bar represents 40 microns. (O’Brien & Wong, 2011) 
 
Figure 1.2. The amyloid cascade.  
The amyloid cascade hypothesis states that Aβ, produced by the BACE-1 and γ-secretase 
mediated cleavage of APP, accumulates as oligomers that cause synaptic and neural 
network dysfunction and tau abnormalities. Aβ-induced damage and/or tau aggregation 
leads to clinically detected impairment in memory that we recognize as AD. In addition, 
Aβ aggregates further as amyloid plaques, which is one of the neuropathological 
hallmarks of AD. (Di Paolo & Kim, 2011) 
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Figure 1.3. Amyloid precursor protein (APP) is processed predominantly in two pathways.  
In the non-amyloidogenic pathway, APP is cleaved by α-secretase, which can be carried 
out by ADAM9, ADAM10 or ADAM17, to release sAPPα and C83 (or CTFα). In the 
amyloidogenic pathway, APP is cleaved by β-secretase, identified as BACE1, to release 
sAPPβ and C99 (or CTFβ). C99 is then cleaved by the γ-secretase complex, composed of 
Presenilin 1 or 2, Nicastrin, PEN2, and APH-1A or B, to release the Aβ peptide and the 
APP intracellular domain (AICD) (LaFerla, Green, & Oddo, 2007). 
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Figure 1.4. APP trafficking has implications for APP processing.  
Non-amyloidogenic cleavage of APP occurs predominantly at the plasma membrane to 
release the sAPPα (APP-sα) fragment, which has neurotrophic properties. Alternatively 
APP is endocytosed into the endosomal pathway where BACE1 cleavage occurs, 
releasing sAPPβ (APP-sβ) luminally and leaving the membrane-bound CTFβ. CTF is 
cleaved by γ-secretase (presenilin 1 or 2 at the catalytic component of the complex) to 
release the Aβ peptide. Although the method of secretion of Aβ peptides remains 
unknown, one method involves the fusion of multivesicular bodies with the plasma 
membrane to release Aβ and endosomal contents, which may be associated with 
exosomes (not pictured) (Rivest, 2009). 
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Figure 1.5. Endosomal sorting of transmembrane proteins and exosome biogenesis.  
Transmembrane proteins, or GPI-anchored proteins in the plasma membrane are 
endocytosed to early endosome (EE). From there, proteins can be sorted into ILVs of 
MVEs (aka MVB) by several mechanisms, including the ESCRT machinery, clustering 
in lipid rafts, or association with the lipid sphingomyelin. ILVs can then be released as 
exosomes extracellularly or degraded in the lysosome. (Bellingham et. al., 2012) 
 
Figure 1.6. Endosomal sorting complex required for transport (ESCRT).  
The ESCRT machinery is series of protein complexes that sort transmembrane cargoes in 
the endosomal membrane. ESCRT-0 recognizes ubiquitinated cargo and prevents it from 
being recycled back into other endosomal pathways. Ubiquitin E3 ligases and 
deubiquitinases (DUBs) dynamically modify ubiquitin chains on protein cargo. After 
recognition, ubiquitinated cargo is transferred to subsequent ESCRT complexes, then the 
endosomal membrane is deformed. Doa4 assists in deubiquitination of proteins to 
maintain the cellular ubiquitin pool and ESCRT pinches off into ILVs containing protein 
cargo. (MacGurn et al., 2012). 
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Figure 1.7. The ubiquitin code.  
A) Ubiquitin can be attached at a single site (monoubiquitination) or as single molecules 
at multiple sites (multi-monoubiquitination). B) Ubiquitin itself can be ubiquitinated at 
one of seven lysine residues to produce polyubiquitin chains on protein substrates to 
convey different cellular signals. C) Different ubiquitin linkages can be combined in 
mixed or branched chains (Wong & Cuervo, 2010). 
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Figure 1.8. Transmembrane protein cellular trafficking events controlled by ubiquitin.  
Ubiquitination was first identified as a signal for proteasomal degradation. Misfolded 
transmembrane proteins that are identified by ubiquitination can be translocated from the 
endoplasmic reticulum to the cytosol for proteasomal degradation in the endoplasmic 
reticulum associated degradation (ERAD) pathway (1). Ubiquitin can also control traffic 
to the Golgi (II), from the Golgi to endosome (III), exocytosis (IV), and recycling from 
the endosomal system to the cell surface (V). In addition, ubiquitin can target 
transmembrane proteins for degradation in the lysosome, by recognizing ubiquitinated 
proteins for endocytosis and/or sorting into the intraluminal vesicles via the ESCRT 
machinery (1-5). (MacGurn et al., 2012) 
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Table 1.1. Overview of AD genome-wide association studies (GWAS) from several 
different groups.  
Pathways show several themes that may provide a clue to AD pathogenesis, including 
events involving endosomal trafficking, highlighted in red. Adapted from (Dong et al., 
2016) 
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2 Chapter 2 APP lysine mutations lead to a deficiency in 
ubiquitination 
Our lab implicated APP as a cargo of the ESCRT pathway after finding a specific 
reduction in the lipid PI3P common to both FAD mouse models and human AD brains in 
areas associated with AD pathology (Morel et al., 2013). PI3P is a master regulator of 
endosomal signaling and recruits Hrs (a component of ESCRT-0), to the endosomal 
membrane via its FYVE domain (Raiborg et al., 2001). The deficit in PI3P provided a 
link to the endosomal dysfunction commonly seen in AD, and led us to hypothesize that 
ESCRT is a crucial sorting pathway for normal APP metabolism. We and others showed 
that APP is a cargo of the ESCRT machinery (Choy et al., 2012; Edgar et al., 2015; 
Morel et al., 2013). However, the amyloidogenic impact of ubiquitin-dependent 
endosomal pathways that govern APP trafficking remain uncertain. Previous studies have 
relied on altering levels of ESCRT components, which are responsible for normal 
endosomal sorting of numerous transmembrane cargos as well as other essential cellular 
events such as cytokinesis. Instead, we chose to investigate the effects of APP lysine-to-
arginine mutants that cannot undergo sorting into ILVs via the ESCRT pathway. Our first 
aim, to characterize the ubiquitination sites in the APP C-terminal domain, allows us to 
better understand how ubiquitin can be a signal for APP trafficking, and thus its 
processing.  
We previously showed that endogenous APP can be ubiquitinated in the mouse brain 
(Morel et al., 2013). We chose to study the effect of mutation of a string of lysine 
residues in the juxtamembrane region of APP, similar to a site that is ubiquitin-modified 
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in other transmembrane proteins (Gupta-Rossi et al., 2004). We mutated these three 
lysines to arginine, to prevent covalent attachment by ubiquitin but maintain the positive 
charge at the residue, and determined that this APP mutant is deficient in ubiquitin when 
expressed in HeLa cells (Morel et al., 2013). As discussed in Chapter 1, two screens of 
the whole cell ubiquitome identified ubiquitination sites on two lysines downstream of 
the triple-lysine juxtamembrane site (Kim et al., 2011; Wagner et al., 2011) and another 
screen of APP interactors identified several elements of the ubiquitin-proteasome system 
(Del Prete et al., 2016). Additional studies have implicated ubiquitination of these two 
downstream lysine residues in regulation of APP processing (El Ayadi et al., 2012; 
Watanabe et al., 2012). We sought to understand the contribution of the five C-terminal 
lysines to ubiquitination of APP and here we show that several APP lysines can be 
ubiquitinated, but that the pool of ubiquitinated APP is likely small or undergoes rapid 
turnover. 
2.1 Results 
2.1.1 Lysine to arginine mutations in the APP C-terminal domain lead 
to a deficiency in APP ubiquitination 
To assess whether the five lysines present in the APP C-terminal domain (Figure 2.1A) 
are sites of ubiquitination, we generated a panel of GFP-tagged APP mutants with each 
lysine mutated to arginine individually and in several combinations. We have previously 
shown that mutation of three consecutive lysines in the juxtamembrane region, K724-
726, to arginine (termed APP3R) leads to a deficiency in endogenous ubiquitination in 
HeLa cells (Morel et al., 2013). APP constructs with individual mutations K724R, 
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K725R, and K726R allow us to identify whether all three of these residues are necessary 
for APP ubiquitination. We generated APP mutant constructs with several combinations 
of lysine-to-arginine mutations, including five individual lysine mutations, the previously 
studied APP3R mutant (K724-726R) as well as APP K751R+K763R, APP K724-
726R+K751R, APP K724-726R+K763R, and mutation of all five lysines, termed APP5R.  
Polyubiquitination occurs when ubiquitin chains assemble at any of seven lysine residues 
of ubiquitin, and can signal different fates for the targeted protein. The most well studied 
chain type is UbK48, which directs protein cargo to the proteasome for degradation. We 
are specifically interested in ubiquitination of APP as a signal for membrane trafficking, 
and as such, we co-expressed APPGFP constructs in cells with UbK48RHA, a ubiquitin 
mutant which cannot form UbK48 polyubiquitin chains, allowing us to study those 
polyubiquitin signals more likely to be involved in trafficking, such as UbK63 
polyubiquitination, or monoubiquitination. To measure the level of ubiquitination of 
these APPGFP mutants, we co-expressed each in HEK293T cells with UbHAK48R, then 
immunoprecipitated the exogenous APPGFP with an anti-GFP antibody and quantified the 
level of ubiquitin via Western blot (Figure 2.1B,C). APPK725RGFP, APPK726RGFP, 
APPK751R,K763RGFP, APP3R + K751RGFP, and APP5RGFP showed significant decreases in 
ubiquitinated APP relative to APPWTGFP. 
2.1.2 Preventing deubiquitinase action reveals ubiquitination of 
APPWTGFP, but not APP5RGFP  
In N2a cells, the ubiquitination of APPGFP was more difficult to detect, possibly because 
of a shorter half-life of ubiquitinated species of APPGFP in this cell line. By co-expressing 
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APPGFP in N2a cells with UbL73PmCherry, a ubiquitin mutant that is resistant to 
deubiquitinases (Békés et al., 2013), we were able to detect an accumulation of 
ubiquitinated APPWTGFP, as compared to cells expressing UbK48RHA. With expression of 
UbL73PmCherry, we could detect a reduction in levels of ubiquitination of APP5RGFP, to 
levels of background signal (Figure 2.2), indicating that APP5RGFP undergoes less 
ubiquitination than APPWTGFP, as predicted. Accumulation of ubiquitinated APP with co-
expression of UbL73PmCherry is consistent with the existence of a pool of transiently 
ubiquitinated APP that leads to a short-lived ubiquitination signal. Although the transient 
nature of this ubiquitin signal makes it difficult to detect, it may represent an important 
regulator of APP trafficking and processing. 
2.1.3 Transience of APP ubiquitination precludes accurate 
identification of ubiquitin chain type 
Since monoubiquitin and polyubiquitin chain identities can serve as a signal for several 
cellular processes, the type of ubiquitin modification that occurs at each lysine in the APP 
C-terminal domain would provide us with several clues as to the signal function. To 
determine the type of ubiquitin modification that predominantly modified APP, we co-
transfected N2a cells with APPWTGFP and ubiquitin mutants, including UbWTHA UbKOHA 
(all ubiquitin lysines mutated to arginine), UbK63HA (all ubiquitin lysines mutated to 
arginine except K63), UbR63HA (only K63 mutated to arginine), and Ub48RHA (only K48 
mutated to arginine) and immunoprecipitated APPGFP (Figure 2.3). Consistent with a 
lower APP ubiquitination signal in N2a cells, we were unable to detect a strong band 
~145kDa correlating to ubiquitinated APP, however we did note a significantly stronger 
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“smear” in the immunoprecipitate of APPWTGFP co-transfected with UbK63HA, suggesting 
that more UbK63 polyubiquitination is associated with APPWTGFP than other chain types. 
To quantitatively assess the ubiquitin modifications, we employed Absolute 
Quantification (AQUA) mass spectrometry whereby heavy isotope labeled synthetic 
peptides are generated and introduced to a sample during proteolytic digestion with 
trypsin. The sample and isotope-labeled AQUA peptides produced by trypsin digestion 
are measured by liquid chromatography selected reaction monitoring (LC-SRM) 
(Kirkpatrick et al., 2005). Trypsin digestion leaves a unique di-glycine signature where 
ubiquitin modification occurred. Specific AQUA peptides can be generated for each 
polyubiquitin linkage, so the composition of polyubiquitin modification at each lysine 
can be determined. We sought to identify modifications of endogenous ubiquitin from 
immunoprecipitated APPGFP and the changes that occur due to lysine mutation. We 
transfected N2a cells with APPWTGFP, APP751R+763RGFP, APP3RGFP or APP5RGFP and 
immunoprecipitated a large amount of starting material (3000mg protein) (Figure 2.4), 
separated precipitated protein by SDS-PAGE and excised three sections of gel above 
~130kDa APPGFP size for mass spectrometry analysis (Figure 2.5). It is worthwhile to 
note that we were able to identify endogenous ubiquitination of APPWTGFP by 
immunoprecipitating APPGFP from this larger amount of starting material, and harvesting 
in the presence of deubiquitinase inhibitors N-ethylmaleimide and 1,10-phenanthroline. 
Based on this immunoprecipitation, we can detect a subtle yet progressive decline in 
ubiquitination from APPWTGFP  à APPK751R+763RGFP à APP3RGFP à APP5RGFP (Figure 
2.4). Although a significant amount of APP-GFP was identified by mass spectrometry, 
only a small portion was ubiquitinated. Despite several attempts to enrich for the pool of 
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ubiquitinated APP – including proteasomal and/or lysosomal inhibition (MG132 and/or 
bafilomycin A1), purification of the endosomal pool of APPGFP, or extraction via a 
stringent urea lysis buffer – we were unable to detect high enough levels of ubiquitinated 
APPGFP to confidently report ubiquitin chain modifications. The small amount of 
ubiquitinated APPGFP detected did indicate that the majority of ubiquitination was in the 
form of UbK48 chains, followed by UbK63 and UbK11, however the levels were too low 
to be meaningfully interpreted (Figure 2.6). The AQUA technique is not ideally suited for 
detection of ubiquitin modifications on multiple lysine residues situated next to each 
other, as occurs in the APP juxtamembrane region. Thus, we were unable to confirm 
ubiquitination at the three lysines K724-6, nor were previous studies that identified APP 
in two screens of the cellular ubiquitome using mass spectrometry (Kim et al., 2011; 
Wagner et al., 2011).
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2.2 Figures 
Figure 2.1. Mutation of APP-770 COOH-terminal lysines leads to a deficiency in APP ubiquitination.  
A) hAPP COOH-terminus domain contains 5 lysine residues that are potential sites of 
ubiquitination. Aβ40 and Aβ42 arrows indicate sites of γ-secretase cleavage. B) 
Representative Western blot of APP ubiquitin immunoprecipitation (IP) in HEK293T 
cells with coexpression of Ub48RHA and APPGFP lysine-to-arginine mutant. Numbered 
headings indicate APP lysine residue(s) mutated to arginine (WT = wild type, 3R = APP 
K724-6R, 5R = all C-terminal lysines mutated, “-“ indicates untransfected). Lysates were 
immunoprecipitated with anti-GFP antibody, and probed with anti-GFP and anti-
ubiquitin (P4D1) antibody. C) Quantification of immunoprecipitated ubiquitin levels, 
normalized to immunoprecipitated APP-GFP and expressed in arbitrary units (A.U.) 
relative to APPWTGFP. Values denote mean +/- SEM, n=4 *P values<0.05, **P 
values<0.01, ***P values<0.001 as measured by one-tailed (due to our ability to make a 
specific hypothesis based on our previous data (Morel et. al., 2013), one sample Student’s 
t-test.   
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Figure 2.2. Ub-APP accumulates with co-expression with deubiquitinase-resistant ubiquitin mutant.  
A) Western blot of APP ubiquitin IP in N2a cells co-expressing APPWTGFP or APP5RGFP 
and UbK48RHA or UbL73PmCherry, precipitated by anti-GFP. Headings indicate both ubiquitin 
mutation (Ub) and APPGFP mutation and a dash indicates no transfection. Lysates were 
immunoprecipitated with anti-GFP antibody and probed with anti-GFP and anti-ubiquitin 
(P4D1). Right panel shows higher exposure of same anti-ubiquitin Western blot.  
 
Figure 2.3. APPWTGFP is predominantly modified by UbK63 polyubiquitination  
A) Western blot of APP ubiquitin IP in N2a cells co-expressing APPWTGFP and 
ubiquitin mutants, precipitated by anti-GFP. Headings indicate mutated lysine(s) of 
ubiquitin: KO = all ubiquitin lysines mutated, 63K = all ubiquitin lysines mutated to 
arginine except K63, 63R = K63 mutated to arginine, 48R = K48 mutated to arginine. 




Figure 2.4. N2a Ub-APP is preserved when cells are harvested in the presence of deubiquitinase 
inhibitors.  
A) Western blot of APP ubiquitin IP in N2a cells expressing APPGFP, precipitated by 
anti-GFP in buffer containing deubiquitinase inhibitors N-ethylmaleimide (NEM) and 
phenanthroline and/or with pretreatment of proteasomal inhibitor MG132. Headings 
indicate APPGFP mutant (2R = K751R+763R) and “-” indicates untransfected sample. 
Western blot is probed with anti-GFP and anti-ubiquitin (P4D1). Right panel represents 
same IP anti-ubiquitin blot at higher exposure.  
 
Figure 2.5. Immunoprecipitated APPGFP is digested by trypsin in the presence of AQUA peptide 
standards for quantification of ubiquitin sites. 
A) Schematic of AQUA strategy. Samples are separated by SDS-PAGED and gel areas 
are excised, then digested with trypsin. AQUA peptide standards are introduced and both 
samples and standards are run in tandem by mass spectrometry to quantify ubiquitination. 
B) Coomassie-stained gel of samples from Figure 2.4 showing regions excised for 
AQUA analysis.  
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Figure 2.6. Polyubiquitin chain quantification from immunoprecipitated APPGFP.  
Gel from Figure 2.5 showing Coomassie stained immunoprecipitated APPGFP from N2a 
cells. Red boxes and numbering indicates area of gel excised for analysis. B) 
Quantification of polyubiquitin chains from each area of excised gels. Note <1fmol 
amounts for most modifications. C) Polyubiquitin chain composition for most abundant 




In this chapter, we find that mutation of several APP C-terminal lysines leads to a 
deficiency in ubiquitination. However, the pool of ubiquitinated APP is difficult to detect, 
likely because ubiquitin is a transient signal and ubiquitinated APP undergoes rapid 
turnover. The technical difficulties in enriching ubiquitinated APP render it difficult to 
detect which polyubiquitin chains decorate the protein. 
2.3.1 APP C-terminal lysines are ubiquitinated 
Several APP mutants showed a decrease in ubiquitination as compared to APPWTGFP, 
indicating that several APP C-terminal lysine residues can be ubiquitinated, or that there 
is a level of redundancy between ubiquitin signals at these residues. There does not seem 
to be one specific lysine that mediates the decrease in APP3RGFP ubiquitination that we 
previously detected in HeLa cells (Morel et al., 2013). Rather, some lysine residues 
appear to be able to compensate when preferred C-terminal lysines are mutated, 
underlining the importance of using the APP5RGFP mutant, which lacks all C-terminal 
lysines in studying downstream processes. Although the APP5RGFP mutant should not be 
ubiquitinated, there was some residual ubiquitin signal in the APPGFP 
immunoprecipitation, which could be attributed to aberrant ubiquitination of NH2-
terminal lysines, GFP ubiquitination, or ubiquitination of APPGFP interacting partners that 
co-immunoprecipitate. We do not expect NH2-terminal lysines to be ubiquitinated as a 
signal for protein trafficking such as endosomal sorting, because the topology of the APP 
protein prevents access of the extracellular/luminal NH2-terminus to ubiquitin E3 ligases 
	 50	
in the cytosol. We attempted to reconcile the residual ubiquitination of 
immunoprecipitated APP5RGFP first by generating C99GFP mutant constructs, 
immunoprecipitation of which would help to rule out ubiquitination of APP at the NH2 
terminus. However, we were concerned that the overexpressed C99 constructs were 
trafficked improperly. We also generated untagged APP lysine-to-arginine mutants, to 
rule out the possibility that the GFP tag itself is ubiquitinated. We did not find any 
difference in level of ubiquitinated APP between GFP-tagged and untagged APPWT, 
APP3R, or APP5R, indicating that the GFP C-terminal tag does not contribute to 
ubiquitination signal. Finally, we immunoprecipitated APPWT, APP3R, or APP5R and 
washed the beads with a high salt wash to prevent co-immunoprecipitation of APP 
interactors that could be ubiquitinated. However, the more stringent conditions did not 
reduce the residual ubiquitination any further.  
We had previously shown a deficiency in ubiquitination of APP3RGFP in studying 
endogenous ubiquitination of APP in HeLa cells (Morel et al., 2013).  However, we did 
not see a similar deficiency in HEK293T cells co-expressing APP3RGFP and UbK48RHA 
(Figure 1C), possibly indicating differences in cell types or in the ubiquitin chain linkages 
modifying the two downstream APP lysines. This discrepancy again emphasizes the 
importance of studying the APP5RGFP mutant to understand the effect of complete lack of 
residues capable of accepting ubiquitin. In fact, the deficiency of ubiquitination of the 
APP mutant K751R+K763R, lacking both downstream C-terminal lysines, was 
approximately equal to that of APP5RGFP, suggesting that these two residues can play an 
important role in APP ubiquitination.  
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2.3.2 The pool of ubiquitinated APP is small or undergoes rapid 
turnover 
The increase in ubiquitinated APP immunoprecipitated from N2a cells expressing 
APPWTGFP with coexpression of UbK48RHA versus deubiquitinase-resistant UbL73PmCherry 
suggests that the pool of ubiquitinated APP is small or rapidly turned over. This is 
consistent with our inability to capture sufficient amounts of ubiquitinated APP to assess 
the ubiquitin chain types decorating the APP cytodomain. Recent work on misfolding-
associated protein secretion showed that cells make a concerted effort to remove 
ubiquitin from quality control substrates prior to secretion, and that similar systems could 
make it difficult to see accumulation of modified APP (Lee et al., 2016). The APP5RGFP 
mutant shows a reduction of ubiquitination in UbL73PmCherry expressing cells to the level of 
untransfected control, and there is a clear effect of lysine mutation, as shown in 
subsequent chapters. Although the small pool of ubiquitinated APP render it difficult to 
detect the type of polyubiquitin modifications that occur on APP, we did detect a stronger 
ubiquitin smear in the immunoprecipitate of N2a cells expressing a ubiquitin mutant that 
has all lysines mutated to arginine except K63, which would correspond to K63 
polyubiquitination. K63 polyubiquitin modification is associated more with protein 
trafficking and endosomal sorting signals than other chain types, which would be 
consistent with the role of APP ubiquitination as a signal for recognition by ESCRT and 
endosomal sorting (Lauwers et al., 2009).  
We recognize that this type of analysis of ubiquitin modification can be skewed by the 
effect of overexpression of a ubiquitin mutant itself. Ubiquitin mutants are a commonly 
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used technique to identify types of protein modification, but the extent to which ubiquitin 
overexpression affects site occupation is unknown. Therefore, we attempted a more 
quantitative analysis by Ub-AQUA mass spectrometry, which was proven useful when it 
provided insights into the trafficking of endosomal growth factor receptor (EGFR), the 
canonical transmembrane protein that undergoes MVE sorting (Huang et al., 2006). 
While application of EGF induces EGFR endocytosis and ubiquitination, full 
quantification of APP ubiquitination was limited by the inability to detect sufficient 
amounts of ubiquitinated APP. Discovery of a ligand inducing APP ubiquitination, an E3 
ubiquitin ligase or deubiquitinase specific for APP would make AQUA analysis of APP 
modifications much more feasible, because levels of ubiquitinated APP could be 
upregulated. This type of analysis could provide more quantitative information about 
ubiquitin modifications than we are able to currently achieve using immunoprecipitation 
and would further guide our knowledge of APP trafficking. 
2.3.3 Other potential lysine modifications of APP 
SUMOylation, the covalent attachment of small ubiquitin-like modifier (SUMO) proteins 
to target proteins, also occurs on lysine residues. SUMOylation can affect multiple 
aspects of protein regulation, including stability, protein interactions and subcellular 
localization (McMillan et al., 2011). Similar to ubiquitination, SUMO must be activated 
by transfer from E1 activating enzyme, to E2 conjugating enzyme and finally to an E3 
SUMO ligase for conjugation to the target protein. In the context of AD mouse models, 
global protein SUMOylation has been shown to be altered, although conflicting studies 
show upregulation and downregulation (Hoppe et al., 2015). Two studies identified an 
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increase in amyloidogenic processing by upregulation of SUMO-2 (Li et al., 2003) or 
SUMO-3 (Dorval et al., 2007) in HEK293 cells, but concluded no direct impact of 
SUMOylation on APP itself. On the other hand, a study by Zhang and Sarge, found a 
SUMOylation motif (ΨKX(E/D) where Ψ is hydrophobic, K is lysine, X is any residue 
and E/D is a glutamate or aspartate residue) near the BACE1 cleavage site of APP. They 
showed that immunoprecipitated APP is modified by SUMO-1 and SUMO-2 and that 
non-SUMOylatable mutants of APP increase levels of Aβ (Zhang & Sarge, 2008). No 
such SUMOylation motif is available in the APP C-terminal domain, suggesting that APP 
would not be SUMOylated when situated in the membrane in its correct topological 
formation.  
Lysine acetylation was originally discovered in the context of histones, however, it can 
play a role in protein regulation. Only less than 90 non-histone proteins have been shown 
to be acetylated, and APP was not a hit on a screen of acetylated proteins in the cytosol of 
HeLa cells (Kim et al., 2006). Another group has identified neddylation of APP after co-
expressing APP-myc and Nedd8-GFP in HEK293 cells, and implicated Nedd8 in 
negative regulation of AICD transcriptional activity by preventing binding of Fe65 (Lee, 
Lee et al., 2008). More work is necessary to determine whether APP is indeed neddylated 
in neurons, at which sites this modification occurs and whether neddylation has an effect 
on Aβ generation.  Although we cannot rule out an effect of disruption of other lysine 
modification of APP, ubiquitin has been well studied for its role in transmembrane 
receptor endocytosis and endosomal sorting. As its name implied, ubiquitin is ubiquitous 
in cells and is a much more abundant post-translational modification than SUMOylation, 
acetylation, and neddylation. The quantitative AQUA method would help to differentiate 
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ubiquitination sites from other post-translational modifications, except for neddylation 
which leaves the same di-glycine signature after trypsin digestion (Kirkpatrick et al., 
2005). Despite the many post-translational modifications that can occur at lysine 
residues, we are confident that ubiquitin is the most important signal contributing to the 
APP processing phenotype that we explore in subsequent chapters. Firstly, ubiquitin is a 
well-defined signal for transmembrane protein trafficking, and secondly, “artificial 
ubiquitination” of APP lysine-to-arginine mutants reverses the APP metabolism defect 
(Chapter 3).  
 
3 Chapter 3 APP Ubiquitin-deficient APP mutants are highly 
metabolized 
3.1 Introduction 
As discussed in Chapter 1, ubiquitination or lack thereof can have an impact on Aβ 
production. Only a few reports identify changes in Aβ levels due to APP ubiquitination 
(Bustamante et al., 2013; Morel et al., 2013; Watanabe et al., 2012), but none provide a 
full picture of APP metabolic changes in APP mutants lacking ubiquitin-binding sites. In 
addition, none of these studies tested the effect of changes in APP ubiquitination on 
levels of intracellular Aβ, which are known to accumulate early in AD (Gouras et al., 
2010). Dysfunction of endosomal sorting pathways, such as retromer, can alter APP 
processing by modulating the interaction time between APP and the secretases. Thus, we 
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hypothesized that disruption of APP ubiquitination can alter APP metabolism by 
interfering with normal endosomal sorting.  
Furthermore, we now have evidence that manipulating ubiquitin regulators can impact 
amyloidogenesis. Deletion of an E3 ubiquitin ligase, Idol, that acts on low-density 
lipoprotein receptor (LDLR) can decrease amyloid burden in a transgenic AD mouse 
model by facilitating ApoE and Aβ clearance (Choi et al., 2015). In a series of studies 
described in Chapter 1, the Tesco lab has shown that BACE1 is regulated by ubiquitin, 
and that depletion of deubiquitinase USP8 can decrease levels of Aβ (Kang et al., 2012; 
Yeates & Tesco, 2016). The identification of a gene encoding ubiquitin regulation 
machinery in a recent AD GWAS directs our attention towards dysfunction of this 
pathway in the clinical realm. In a population of Caribbean Hispanics with AD, this 
GWAS identified a candidate E3 ubiquitin ligase component, F-box and leucine-rich 
repeat protein 7 (FBXL7), as a risk factor for AD (Tosto et al., 2015). Thus, ubiquitin can 
be an important regulator of cellular processes leading to Aβ generation, and elucidation 
of this pathway could add to our understanding of the pathogenesis of AD and lead to 
potential new targets for therapeutics. 
We hypothesized that disrupting sites of ubiquitination of APP would lead to changes in 
Aβ generation that occur due to disruption of normal endosomal trafficking. Since 
analysis of APP lysine mutations did not reveal any one specific residue responsible for 
APP ubiquitination, we chose to first study APP metabolism in the panel of APP lysine-
to-arginine mutants. Here, we show that APP lysine-to-arginine mutations lead to an 
increase in APP processing, and a selective increase in Aβ40 intracellularly and 
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extracellularly, which can be rescued by artificial ubiquitination of the most highly 
processed APP5R mutant. Furthermore, a screen of deubiquitinases in C. elegans led to 
identification of ubiquitin specific protease 5 (USP5), depletion of which can reduce 
levels of secreted Aβ. 
3.2 Results 
3.2.1 APP lysine-to-arginine mutants undergo increased APP 
metabolism 
We first investigated the effect of ubiquitin deficiency on the metabolism of APP in 
cultured cells. We expressed APPGFP lysine-to-arginine mutants in N2a cells, and 
measured the fragments that are produced by cleavage of full-length APPGFP by Western 
blot or ELISA (Figure 2A). N2a cells were used instead of HEK293 cells because (1) 
they are of neural origin, (2) they release detectable amounts of Aβ42 and (3) their mouse 
origin allows us to distinguish exogenous human APPGFP fragments from endogenous 
murine APP.  
When expressed in N2a cells, all APPGFP lysine–to-arginine mutants exhibited decreased 
amount of full-length APP. Consistent with increased processing of APP, we detected 
higher levels of the sAPPα and sAPPβ secreted into the culture media. There was a trend 
toward an increase in processing with the number of APP lysines mutated, such that the 
APP5RGFP mutant, with no remaining lysines in the C-terminal domain, underwent the 
most extensive processing. Compared to APPWTGFP, the APP5RGFP mutant had an 
approximate reduction of full-length APP of 50% and a corresponding 3-fold increase in 
cleaved soluble fragment sAPPα and 2-fold increase in cleaved soluble fragment sAPPβ, 
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normalized to the expression levels of full-length APPGFP. In line with increase 
processing, APPGFP lysine–to-arginine mutants led to a selective increase in secreted 
Aβ40, with no change in Aβ42, thus causing a significant decrease in Aβ42/40 ratio 
(Figure 3.1).  
We chose to focus further analysis on two APP mutants: APP3R, which has a cluster of 
three lysines in the juxtamembrane region mutated to arginine, and APP5R, which has the 
strongest phenotype in terms of APP processing. Importantly, we confirmed that the 
APP3RGFP and APP5RGFP mutants are similarly processed in primary neuronal cultures, 
using lentiviral-mediated expression of APPGFP. While the APP3RGFP mutant (published in 
Morel et al., 2013) exhibits a selective increase in Aβ40 and only a trend for an increase 
in sAPPβ (Figure 3.2), the APP5R phenotype is more pronounced, leading to a significant 
increase in both sAPPα and sAPPβ, in addition to an increase in Aβ40 and decrease in 
Aβ42 (Figure 3.3). APP-CTF was not detectable in neuronal cultures under basal 
conditions, however a single band appears upon treatment with γ-secretase inhibitor, 
likely representing both C83 and C99. APP5R CTF accumulates ~75% more than APPWT 
CTF after γ-secretase inhibition, suggesting that γ-secretase cleaves more APP5R CTF 
than APPWT CTF.  
To determine whether the change in the Aβ42/40 ratio in the cell media is due to 
increased production of Aβ40, or to decreased secretion of Aβ42, we analyzed levels of 
intracellular Aβ in N2a cells expressing APP mutants. Levels of intracellular Aβ40 are 
increased in cells expressing APP5RGFP compared to APPWTGFP, with a trend for an 
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increase in cells expressing APP3RGFP (Figure 3.4). Thus, substitution of APP C-terminal 
lysines leads to a selective increase in both secreted and intracellular Aβ40.   
3.2.2 Accumulation of Aβ40 can be reversed by “artificial 
ubiquitination” of APP 
To confirm that the increase in Aβ40 generation of APP lysine-to-arginine mutants is due 
to deficiency of ubiquitination we sought to “rescue” this phenotype by artificially 
ubiquitinating the APP3R and APP5R mutant. We generated constructs to express 
dimerizable APP and ubiquitin with DmrA and DmrC tags, respectively, based on a 
commercially available rapalog-induced dimerization system (Clackson et al., 1998; 
Crabtree & Schreiber, 1996). By expressing APPDmrA and UbDmrC in N2a cells and adding 
A/C heterodimerizer, we can induce physical proximity between APPDmrA and UbDmrC 
(Figure 3.5A). Indeed, artificial ubiquitination of APP3RDmrA or APP5RDmrA reduced levels 
of secreted Aβ40 back to APPWTDmrA after treatment of heterodimerizer compared to 
control solution (ethanol) (Figure 3.5C). The reduction in Aβ is not likely due to an 
increase in APPDmrA degradation, since levels of full-length APPDmrA are higher in 
heterodimerizer-treated cells as compared to control-treated cells (Figure 3.5B). Thus, the 
chemically-induced addition of ubiquitin to the C-terminal domain of APP mutants that 
are deficient in ubiquitination is sufficient to prevent the increase in Aβ40, lending 
further support to the notion that this phenotype is due to a ubiquitin deficiency. 
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3.2.3 Aβ profile is not replicated by APP mutants in a cell-free assay 
Since the APP lysine-to-arginine mutations include residues close to the γ-secretase 
cleavage site, we checked whether the increase in processing by γ-secretase could be due 
to a change in the interaction between γ-secretase and the APP mutant independently of 
potential differences in intracellular protein sorting. To this end, we generated C99 
substrates including the APP3R and APP5R mutations and subjected them to cleavage in a 
cell-free γ-secretase assay (Figure 3.6). Neither the APP3R nor the APP5R C99 substrates 
exhibited an increase in Aβ40, as occurs in cell culture. In fact, there was a significant 
decrease in levels of Aβ40 produced by APP3R C99 and no change in production of 
Aβ42. Thus, the increase in Aβ40 secretion that occurs in cell culture is not simply due to 
an intrinsic change in the interaction of APP mutants with the γ-secretase complex 
3.2.4 USP5 deubiquitinase reduces Aβ levels 
We have shown that artificial ubiquitination of APP using a heterodimerizer system in 
N2a cells can reduce the levels of secreted Aβ40 and Aβ42. We hypothesized that 
depletion of an APP DUB would have a similar effect by increasing levels of APP 
ubiquitination, thereby driving APP into ILVs and sequestering APP from secretase 
cleavage. We screened for candidate APP DUBs in C. elegans, which contain a 
manageable number of DUBs that have a mammalian ortholog. Unlike humans who 
express APP and two related genes, (amyloid-beta precursor like protein) APLP-1 and 
APLP-2, C. elegans have only one member of this family, known as apl-1, which is 
essential for viability (Ewald & Li, 2012). We studied 30 strains of C. elegans with 
enhanced RNAi in the nervous system against a specific DUB, and crossed them to 
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another strain that expresses APL-1-GFP under a GABA-ergic promoter (Figure 3.7A). 
By imaging cell bodies of neurons in each, six strains were noted to have a change in 
APL-1-GFP levels measured by average fluorescence in a preliminary screen of 5 cells 
per strain. An additional 25 cells were imaged in a second round of analysis, and the 
same six strains were identified as modulating APL-1-GFP levels. Only one C. elegans 
strain exhibited an increase in levels of APL-1 via immunofluoresence, ubiquitin specific 
protease (USP)5, while others exhibited a decrease in immunofluorescence, USP-47, 
USP-14, C10C6.3, OTUB-1 (OTU Deubiquitinase, Ubiquitin Aldehyde Binding-1), and 
USP-33 (Figure 3.7B).  
Two of these DUBs, USP5 and OTUB1, were recently shown to bind to the APP 
cytosolic region in a screen of ubiquitin-related APP interactors (Del Prete et al., 2016). 
We chose to initially focus attention on USP5 since 1) an increase in APL-1 is less likely 
to indicate ubiquitin-induced degradation of APL-1 and 2) OTUB-1 has been reported to 
have more specificity for K48 polyubiquitin chains than K63 polyubiquitin chains (Ewald 
& Li, 2012). We successfully knocked down USP5 in N2a cells (Figure 3.7) and found 
that USP5 depletion decreases the levels of secreted Aβ40 and Aβ42 in APP5RGFP-
expressing cells, with only a trend for a decrease in Aβ levels in APPWTGFP-expressing 
cells (Figure 3.8). Although much work needs to be done to confirm whether USP5 and 
APP physically interact, it is clear that deubiquitinase inhibitors have potential as a tool 
to modulate APP metabolism.  
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3.3 Figures 
Figure 3.1. Metabolism of APP KàR mutants is altered in N2a cells.  
Representative Western blot of full-length APPGFP and actin from cell lysate and sAPPα 
from cell media of N2a cells expressing APPGFP lysine-to-arginine mutants. Numbered 
headings indicate APP lysine residue(s) mutated to arginine (WT = wild type, 3R = APP 
K724-6R, 5R = all C-terminal lysines mutated). B) Quantification of full-length APPGFP 
and sAPPα from Western blot, and quantification of Aβ40, Aβ42 and sAPPβ by ELISA 
of cell culture media. Full-length APPGFP is normalized to actin loading control and 
sAPPα, sAPPβ, Aβ40 and Aβ42 are normalized to APPGFP. All are expressed in arbitrary 
units (A.U.) relative to APPWTGFP. Values denote mean +/- SEM, n=5-7 *P values<0.05, 
**P values<0.005,  as measured by one sample Student’s t-test. 
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Figure 3.2. Expression of the APP3RGFP mutant leads to an increase in secreted Aβ40.  
Mouse neurons were infected with lentivirus expressing human APPWTGFP and APP3RGFP 
at DIV 7. At DIV 14, secreted APP metabolite sAPPα was analyzed by Western blot (in a 
and b), while secreted APP metabolite sAPPβ was measured by ELISA of culture media 
(in c). Synaptotagmin was used as an equal loading marker. The graphs show the 
quantification of full length APP normalized to synaptotagmin (in a) and the 
quantification of metabolites sAPPα (in b) and sAPPβ levels (in c) as a ratio of 
metabolite/full length APPGFP. Values denote means ± SEM (n=8). 
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Figure 3.3. APP5RGFP is extensively metabolized by secretases in primary neurons.  
APPWTGFP or APP5RGFP was expressed in primary murine cortical neurons via lentivirus at 
DIV 7, and cell lysate and culture media was harvested at DIV 14. Gamma-secretase 
inhibitor XXI was applied at 2uM to indicated samples, for 24 hours before harvest A) 
Representative Western blot of full-length APPGFP and synaptotagmin (used as an equal 
loading marker) from cell lysate and sAPPα from cell media. B) Quantification of full-
length APPGFP and sAPPα from Western blot, and quantification of sAPPβ by ELISA of 
cell culture media. Full-length APPGFP is normalized to synaptotagmin loading control 
and sAPPα and sAPPβ are normalized to APPGFP. C) Quantification of Aβ40 and Aβ42 
levels measured by ELISA and normalized to full-length APP, and ratio of Aβ42/ Aβ40. 
D) Quantification of APP-CTFGFP, normalized to full-length APP in cells treated with γ-
secretase inhibitor XXI. All are expressed in arbitrary units (A.U.) relative to APPWTGFP. 
Values denote mean +/- SEM. Number in bar refers to number of samples in 4 separate 
dissections (3 dissections in (D)). *P values<0.05, **P values<0.01, as measured by 
Student’s t-test.  
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Figure 3.4. Intracellular Aβ40 is increased in APP5RGFP expressing N2a cells. 
A) Aβ40 and Aβ42 measured in cell lysate of N2a cells expressing APPWTGFP, APP3RGFP, 
or APP5RGFP via ELISA. Equal concentrations of protein, as measured by BCA assay, are 
loaded for each sample and values are expressed in arbitrary units (A.U.) relative to 
APPWTGFP. Values denote mean +/- SEM, n=6-8 *P values<0.05, as measured by one 
sample Student’s t-test  
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Figure 3.5. Chemically induced colocalization of APP and ubiquitin prevents APP3R and APP5R - 
mediated increase in Aβ40 levels.  
A) Diagram describing the dimerization of DmrA and DmrC domains fused to APP and 
ubiquitin, respectively, after addition of A/C heterodimerizer to culture media. B) 
Representative Western blot of N2a cells expressing APPDmrA-RFP alone or co-expressing 
APPDmrA-RFP and UbDmrC were treated for 24 hours with control solute ethanol or 
heterodimerizer. Headings indicate which APPDmrA-RFP mutant was expressed. Actin was 
used as an equal loading marker. C) Cell culture media from (B) was measured for levels 
of secreted Aβ40 and Aβ42 measured via ELISA and values are expressed in arbitrary 
units (A.U.) relative to WT APPDmrA-RFP alone. Values denote mean +/- SEM, n=3-6) *P 
values<0.05, **P values<0.01, ***P values<0.001 as measured by one sample Student’s 




Figure 3.6. Gamma secretase cleavage does not 
produce more Aβ40 from APP3R or APP5R in a cell 
free assay.  
Levels of Aβ40 and Aβ42 from in vitro γ secretase assay. Purified APP C99-FLAG 
substrate is incubated with purified γ-secretase membranes and resultant Aβ levels are 
measured via ELISA. Aβ40 and Aβ42 levels are expressed in arbitrary units (A.U.) 
relative to WT C99. Values denote mean +/- SEM, n=3 *P value<0.05, as measured by 
one sample Student’s t-test  
in vitro γ-secretase assay 
Marty Fernandez 
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Figure 3.7. RNAi screen for APL-1 DUBs in C. elegans.  
A) C. elegans strains expressing APL-1::GFP under GABAergic promoter crossed with 
strains with RNAi against DUBs revealed 6 strains with changes in fluorescence of APL-
1::GFP in the cell body of neurons. Arrows indicate APL-1-GFP in neuronal cell bodies. 
B) Levels of APL-1-GFP fluorescence in 6 strains identified to be different from control 
(lacking specific RNAi). Strains with USP5 RNAi had APL-1-GFP levels higher than 
control while USP47, USP14, Y55F3AM.15, OTUB1, and USP33 RNAi strains had 
lower APL-1-GFP levels. Values denote mean +/- SEM 
Dr. Peter Juo 
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Figure 3.8. Knockdown of ubiquitin-specific protease 5 (USP5) decreases Aβ in APP5R.  
A) Representative Western blot of N2a cells treated with non-targeting (CTRL) or USP5 
siRNA and expressing APPGFPWT or APPGFP5R. B) Quantification of Western blot for full-
length APP (FL-APP) and USP5 normalized to actin C) Secreted Aβ measured by ELISA 
from culture media, normalized to levels of FL-APP. Values are relative compared to 
APPWT CTRL condition, and expressed in arbitrary units (A.U.) Values denote mean +/- 
SEM, n=9) *P values<0.05, **P values<0.005, ***P values<0.001 as measured by 
Student’s t-test 
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APPL, Zebrafish APPa, Xenopus APP-A and the human APP, APLP1 and APLP2.  
Purple sequences indicate identical homology while green references similar amino acids. 
Black box indicates YENPTY motif, blue box indicates transmembrane domain and red 
box indicates Aβ sequence. Orange box indicates single lysine in the C. elegans APL-1 
C-terminal domain, and yellow boxes indicate 5 lysine resides in human APP C-terminal 
















In this chapter, we find that altering ubiquitination sites of APP can have dramatic effects 
on APP metabolism, including an increase in processing of full-length APP by both α- 
and β-secretase, which in turn provides additional substrate for cleavage by γ-secretase 
and increases Aβ generation. Interestingly, we find that the increase in Aβ is specific to 
Aβ40, as opposed to Aβ42, which is more aggregate prone and commonly increased in 
EOAD and disease models of AD, and that the increase can be prevented by artificial 
ubiquitination of APP or depletion of the deubiquitinase USP5. 
3.4.1 Role of APP ubiquitination in Aβ generation  
In previous studies that identified ubiquitination of APP, only one has studied the role of 
ubiquitination in Aβ generation. Watanabe et al. showed that FBL2 induces 
ubiquitination of APP in the presence of MG132. They used APP lysine mutants to 
determine that residue K726 mediates FBL2-induced ubiquitination, however, they used 
lysine-to-alanine mutants, which alters the protein charge in the critical juxtamembrane 
region for γ-secretase cleavage (Xu et al., 2016). Nonetheless, FBL2 overexpression 
reduced levels of secreted sAPPβ (but not sAPPα), Aβ40 and Aβ42 in HEK293 cells and 
reduced levels of intracellular Aβ40 in N2a cells stably expressing APP with the Swedish 
mutation. Upon FBL2 overexpression, APP also accumulated on the cell surface, which 
led to their hypothesis that FBL2 induces APP ubiquitination to promote degradation via 
the proteasome (Watanabe et al., 2012). This hypothesis needs further review since 
transmembrane proteins are not generally known to be degraded by the proteasome from 
the plasma membrane, however, FBL2 is worth further exploration as a candidate 
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component of an APP ubiquitin E3 ligase. We chose to focus further study on baseline 
APP ubiquitination that does not rely on proteasomal inhibition. In our initial study, we 
found that the APP3RGFP mutant is ubiquitin-deficient in HeLa cells and leads to a 
selective increase in Aβ40 when expressed in primary neurons (Figure 3.2, published in 
Morel et al., 2013). Based on our results from Chapter 2, we sought to analyze APP 
metabolism in the full panel of APP lysine-to-arginine mutants. 
Levels of full-length APP were consistently decreased in the APP lysine-to-arginine 
mutants, which suggests that the main purpose of the ubiquitination signal is not simply 
to direct the protein for degradation, which would instead lead to accumulation of full-
length APP mutants. Furthermore, the reduction is not likely to be a downregulation of 
transcription because the human APPGFP is expressed from an exogenous cDNA 
construct under the CMV promoter. Rather, we believe that ubiquitination of APP is an 
important signal for intracellular trafficking of APP. The reduction in full-length APP is 
more likely due to cleavage of an additional pool of APP that would not otherwise 
interact with α-, β- or γ-secretases.  
The “dose-dependent” effect of the number of lysines mutated is consistent with ubiquitin 
as a redundant signal, which can occur anywhere in the vicinity of the C-terminal 
domain, as discussed in Chapter 2. The most significant effect is observed with the APP5R 
mutant, lacking all five C-terminal lysines. In primary neurons, we show that mutation of 
all five C-terminal lysine residues APP5RGFP has a stronger phenotype than APP3RGFP in 
terms of APP processing, with a significant increase in levels of sAPPα and sAPPβ for 
APP5RGFP only. In fact, several phenotypes – including accumulation of Aβ40 
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intracellularly, and reduction of basal levels of APP-CTF – show a trend for the APP3RGFP 
but are only significant for APP5R. In agreement with Chapter 2, this suggests that the 
three juxtamembrane lysines mutated in APP3R are important sites of ubiquitination in 
regards to APP metabolism, however the two downstream lysines are also capable of 
ubiquitin modification to mediate ubiquitin signaling.  
Importantly, chemically inducing a physical interaction between ubiquitin and APP 
cytodomain was sufficient to decrease the levels of secreted Aβ, even though the artificial 
ubiquitin modification was at the distal end of APP, suggesting that the specific location 
of ubiquitination sites may not be as critical as the extent of ubiquitination present on the 
cytodomain. In fact, in some of the first studies of ubiquitin as a signal for 
transmembrane receptor trafficking, it was shown that fusion of ubiquitin to the COOH-
terminus was sufficient to drive receptor mediated endocytosis or signal sorting for 
lysosomal degradation (Haglund et al., 2003; Nakatsu et al., 2000). Moreover, fusion of 
ubiquitin to the transferrin receptor, which normally traffics to the recycling pathway, 
redirects the receptor towards Hrs binding and the degradative endosomal pathway 
(Raiborg & Stenmark, 2002). In summary, APP lysine-to-arginine mutants that cannot 
undergo ubiquitination have a phenotype consistent with increased metabolism of APP 
by secretases, which is not simply due to a degradation defect, but rather might be related 
the role of ubiquitin in transmembrane protein trafficking.  
3.4.2 α-secretase and BACE1 need not compete for APP cleavage 
We noted in our lysine-to-arginine APP mutants that both sAPPα and sAPPβ levels are 
increased, suggesting that the APP mutants are cleaved more by both α-secretase and 
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BACE1. Since α-secretase and BACE1 compete for cleavage of full-length APP, it has 
been suggested that there is a reciprocal nature to these events and that upregulation of α-
secretase cleavage would be of therapeutic benefit in AD (Fahrenholz & Postina, 2006). 
Many of the studies that led to this hypothesis employed overexpression or activation to 
enhance levels of one secretase, and measured the effects on the other. On the other hand, 
Colombo et al. used depletion of endogenous ADAM10 or BACE1 to show that there 
was no inverse coupling in certain cell lines, but there was an increase in ADAM10 
cleavage of APP upon BACE1 depletion in neurons (Colombo et al., 2013). Likewise, 
BACE1 inhibition led to an increase in sAPPα in CSF in monkeys, and in human iPSCs 
(Ben Halima et al., 2016; Dobrowolska et al., 2014). Thus, the interaction between 
ADAM10 and BACE1 is not entirely understood, and may differ depending on cell line, 
but BACE1 inhibition could have an additional therapeutic effect of increasing α-
secretase processing. In our study, we did not see an effect of reciprocal α-/β-secretase 
processing. Both N2a cells and primary neurons expressing APP5RGFP led to an increase 
in both sAPPα and sAPPβ in the cell media. This dual increase in processing could reflect 
additional APP substrate available to both α-secretase and BACE1 due to an altered 
cellular trafficking itinerary, instead of an increased processing ability by either secretase. 
3.4.3 Ratio of Aβ42/40 and AD pathology 
The most striking phenotype of the APP5R mutant is the selective increase in Aβ40 and 
resulting decrease in the Aβ42/40 ratio. It was recognized early on that Aβ40 and Aβ42 
have different kinetics in terms of fibrillar assembly, that Aβ40 can interrupt Aβ42 
aggregation in a concentration-dependent manner (Snyder et al., 1994), and that most 
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FAD mutations lead to an increase in total Aβ production, or skew cleavage towards 
longer, more aggregate-prone species of Aβ thereby increasing the Aβ42/40 ratio 
(Bateman et al., 2011). Recent structural analysis of Aβ42 fibrils reveal properties of the 
Aβ42 fibril structure due to the last two amino acids that would make it highly unlikely 
for Aβ40 to form fibrils (Tycko, 2016). The main component of parenchymal amyloid 
plaques is Aβ42, while vascular aggregates in cerebral amyloid angiopathy (CAA) have a 
predominance of Aβ40 (Iwatsubo et al., 1995; Mann et al., 1996). Several studies since 
have investigated the role of Aβ species in aggregating in vitro, and show that Aβ40 
slows the aggregation of Aβ42, and can inhibit Aβ42-induced toxicity (Bate & Williams, 
2010; Jan et al., 2008; Pauwels et al., 2012; Yan & Wang, 2007). In mice expressing 
fusion proteins to increase the production only of Aβ42 or Aβ40 in vivo, without APP 
overexpression, Aβ42 was required for plaque formation and generated both parenchymal 
and vascular amyloid pathology that was absent in Aβ40-expressing mice (McGowan et 
al., 2005). Crossing the Aβ-overexpressing mice with a transgenic FAD mouse model led 
to a dramatic reduction of amyloid pathology in the Aβ40-expressing mice, suggesting 
that Aβ40 can prevent plaque formation in vivo (Kim et al., 2007). These studies support 
the notion that decreasing the Aβ42/20 ratio by increasing Aβ40 could be of therapeutic 
use in AD, however, the effects on cerebral amyloid deposition are largely unknown. A 
recent study of transgenic mice expressing both Dutch and Iowa CAA mutations in the 
Aβ region (on a Swedish APP background), shows that the predominant Aβ species in 
vascular deposits is Aβ40, which is commonly seen in these variants (Van Nostrand et 
al., 2002). The worrisome aspect of the study is that the majority of the Aβ40 in the 
deposit was wild-type Aβ, as opposed to Aβ carrying the Dutch/Iowa mutation, 
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suggesting that transgenic amyloid seeds could drive assembly of wild type Aβ40 into 
deposits in the vasculature (Xu et al., 2016). It is unclear whether this phenomenon is 
specific to these mutations in the Aβ sequence, or whether nucleation of any Aβ could 
encourage further aggregation of Aβ40. If the APP lysine-to-arginine mutants produce 
the same Aβ profile in vivo, they may also prevent oligomeric assembly and plaque 
deposition in the parenchyma, but could contribute to vascular pathology. In any case, 
these APP lysine-to-arginine mutants are perfectly suited to studying the effect of Aβ40 
increase in vivo from full-length APP cleavage, as opposed to expression of transgenic 
Aβ fusion constructs.  
APP5RGFP also showed a selective increase in Aβ40 extracellularly and intracellularly, 
which suggested that the phenomenon is not due to a differential effect on secretion of 
Aβ species, but rather to an increase in Aβ40 generation overall. Aβ is known to 
accumulate intracellularly at early stages of AD, but specifically Aβ42 (Gouras et al., 
2000). Mice engineered to overexpress Aβ40 or Aβ42 only intracellularly showed 
toxicity and degeneration in the Aβ42-, and not Aβ40-expressing mice (Abramowski et 
al., 2012). At this stage, we cannot predict whether an increase in Aβ40 would be 
protective intracellularly, but there is some evidence that Aβ42 causes a pathogenic 
conformational change in PSEN1 in neurons, which is prevented by higher levels of 
Aβ40, up to a certain limit (Zoltowska et al., 2016). Finally, we cannot rule out an 
accumulation of insoluble Aβ in our APP5RGFP expressing cells, since our study was 
limited to measurement of Aβ in RIPA-soluble fractions. We attempted to express the 
mutant APP constructs in mice via in utero electroporation, however, the levels of 
exogenous APP and Aβ were insufficient for analysis at 6 weeks and 6 months. 
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Lentivirus-mediated injection into the adult mouse brain would be a better suited 
technique for this type of study. It will be important to confirm whether these lysine-to-
arginine APP mutants also generate a selective increase in Aβ40 in vivo, in order to 
identify any beneficial or detrimental effect, and to determine whether additional Aβ40 
can cause CAA pathology. This has important implications in understanding mechanisms 
of action of γ-secretase modulators, which aim shift the C-terminal cleavage of Aβ to 
increase the relative amount of shorter Aβ species. 
3.4.4 USP5 decreases Aβ levels for APP-5R 
The identity of DUBs acting on APP remain unknown, though an estimated 95 putative 
DUBs exist in the human genome (Nijman et al., 2005). Although there are more E3 
ubiquitin ligases than DUBs, many DUBs are indeed known to exhibit a restricted 
specificity to select substrates, and several DUB inhibitors are currently being 
investigated for a role in therapeutics, especially in terms of cancer treatments (Zhang & 
Sidhu, 2014). C. elegans APL-1 shares 71% sequence similarity to human APP in the 
intracellular domain, though it lacks the Aβ sequence (Ewald & Li, 2012). In addition, 
APL-1 contains only one lysine residue in the C-terminal domain capable of ubiquitin 
modification (Figure 3.9). Nonetheless, one lysine residue is sufficient to signal cellular 
trafficking events, as evidenced by BACE1 endocytosis (Kang et al., 2012). More work 
would be necessary to determine whether USP5 specifically interacts with APP or 
whether the Aβ effect is due to USP5 action on other APP processing or trafficking 
machinery. Since APP5R does not contain C-terminal lysines that can be ubiquitinated in 
the first place, it seems counterintuitive that depletion of USP5 would have an effect on 
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Aβ production due to APP interaction alone. It is possible that USP5 depletion leads to 
aberrant ubiquitination such as non-lysine ubiquitination. Based on the heterodimerizer 
experiment, we know that ubiquitin need only be localized in the general C-terminus 
region to effectively reduce APP5R Aβ levels. However, it seems more likely that USP5 
depletion leads to an increase in degradation of APP, or that it interacts with another 
protein that has downstream effects on APP cleavage. Further exploration of the effects 
of USP5 is necessary, but this experiment suggests that deubiquitinase inhibitors might 
be an attractive avenue of exploration for Aβ-reducing therapeutics.  
 
4 Chapter 4 Altered trafficking of ubiquitin-deficient APP 
mutants 
4.1 Introduction 
The trafficking of APP is intimately linked to its processing, since small alterations in 
localization of APP or the secretases can have profound effects on APP metabolism. It is 
now well established that endosomes represent a key intracellular station for APP 
processing and that endosomal dysfunction is a pathophysiological hallmark of AD 
(Gouras, 2013; Nixon, 2005; Toh et al., 2016). Several susceptibility genes associated 
with LOAD from genome wide association studies (GWAS) are endosomal regulators 
(Hollingworth et al., 2011; Lambert et al., 2013; Tosto & Reitz, 2013), and specific 
defects in endosomal sorting pathway components have been associated with LOAD 
(Peric & Annaert, 2015; Small & Gandy, 2006). APP and its proteolytic enzymes are 
	 78	
transmembrane proteins that traffic through the secretory pathway and endo-lysosomal 
system, and thus the sorting and compartmentalization of these proteins dictates 
processing of APP into Aβ and other fragments. In normal neuronal metabolism, Aβ is 
produced and secreted from the cell at low levels. However, intraneuronal increase in Aβ 
precedes the gross pathological changes of AD. AD-affected neurons accumulate Aβ, 
particularly in MVEs (Takahashi 2002, 2004). ILVs are formed by invagination of the 
MVE limiting membrane, which can sequester membrane cargo inside. In ILVs, cargo 
can be sorted into several fates including lysosomal degradation and secretion 
extracellularly as exosomes. Sorting of transmembrane proteins can be controlled by 
ubiquitination, a posttranslational modification that can signal transmembrane proteins 
for ERAD, endocytosis or MVB sorting. We hypothesize that the APP lysine-to-arginine 
mutants exhibit increased APP metabolism because the lack of ubiquitination prevents 
ESCRT recognition. Accumulation of APP on the endosomal limiting membrane allows 
increased interaction with the secretases, and generation of Aβ. We also expect that APP 
lysine-to-arginine mutants will not be sorted into ILVs, and will have downstream effects 
on exosomal content or lysosomal degradation.  
A recent paper by Sannerud et al., 2016 suggested that the subcellular localization of 
PSEN1 and PSEN2 is vastly different. Specifically, they localized PSEN2 to the limiting 
membrane of the endosome, reminiscent of APP5R endosomal localization. In addition, 
the authors show that cleavage by PSEN2-containing complexes leads to an increase in 
intracellular Aβ, another phenotype of the APP5R mutant. We hypothesized that the 
increase in Aβ40 generated by APP5R may be due to increased cleavage by PSEN2-
containing γ-secretase complexes. Here, we show that APP lysine-to-arginine mutants 
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APP3R and APP5R are redistributed from the endosomal lumen to the limiting membrane, 
which leads to a deficiency in APP-CTF exosomal content, but not to a delay in 
lysosomal degradation. Furthermore, we show that PSEN2 depletion significantly 
reduces the APP5RGFP-mediated increase in Aβ40, suggesting PSEN2-containing γ-
secretase complexes cleave an additional pool of APP-CTF that accumulates on the 
limiting membrane of the endosome.  
4.2 Results 
4.2.1 APP ubiquitination is required for efficient sorting into ILVs 
As membrane-bound cargo traffics through the endo-lysosomal system, it undergoes 
sorting at the endosomal membrane. Ubiquitin is a known signal for ESCRT recognition, 
which is responsible for sorting cargo ILVs of MVEs. As shown previously (Morel et al., 
2013), APP is a cargo of ESCRT and APP3R accumulates on the endosomal limiting 
membrane instead of being sorted onto ILVs. To distinguish endosome limiting 
membrane and endosome interior (i.e., ILVs), we artificially generated larger endosomes 
by co-expressing APPGFP with Rab5Q79L in N2a cells. In addition to APP3RGFP, 
APP5RGFP is also mislocalized from the endosome interior to the endosome periphery 
(Figure 4.1A,B). As amyloidogenic cleavage of APP occurs primarily on the endosomal 
membrane, prevention of APP sorting into ILVs could increase interaction between APP, 
BACE1, and γ-secretase, increasing processing of APP and generation of Aβ. Airyscan 
confocal microscopy uses a specialized detector array that allows inclusion of fluorescent 
signal that would otherwise be rejected by the single confocal pinhole, and enhances the 
resolution by a factor of 1.7. Airyscan images show multiple examples of round 
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APPWTGFP-positive vesicles inside of enlarged Rab5Q79LmCherry-positive vesicles, which 
are absent in APP3RGFP and APP5RGFP-expressing cells, and thought to be APPGFP located 
on ILV membranes (Figure 4.1C).  
4.2.2 APP lysine-to-arginine mutation does not affect APP endocytosis 
We hypothesized that the increase in secreted sAPPα in cells expressing the APP lysine-
to-arginine mutants could be due to an accumulation of APP mutants on the cell surface, 
since ubiquitin can be a signal for endocytosis at the plasma membrane. To determine 
whether cell surface levels of APP3RGFP and APP5RGFP were increased compared to 
APPWTGFP, we expressed each in N2a cells and carried out a cell surface biotinylation 
assay. Briefly, we labeled surface proteins with biotin, then precipitated biotinylated 
proteins after quenching and washing the cells. We compared cell surface to total APP 
via Western blot of biotinylated fraction versus total cell lysate and found no difference 
in cell surface levels of APP (Figure 4.2). Thus, lysine mutation of APP does not appear 
to cause cell surface accumulation.  
4.2.3 APP lysosomal degradation is largely unaffected by APP lysine-
to-arginine mutation 
Protein cargo sorted onto ILVs can undergo several fates. Two downstream pathways of 
ILVs include degradation of ILVs and cargo via the lysosome, or extracellular release of 
ILVs as exosomes. The missorting of APP3R and APP5R led us to hypothesize that one or 
both of these downstream pathways could be affected. To determine whether lack of APP 
ILV sorting would affect degradation of APP full-length or CTFs, we measured the levels 
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of each in N2a cells after treatment with cycloheximide (Figure 4.3). Because the APP-
CTFs are rapidly degraded by γ secretase, we applied γ-secretase inhibitor to identify 
differences in APP-CTF degradation that is not due to γ-secretase cleavage. We did not 
detect any striking differences in APP-CTF degradation between APPWT and APP3R or 
APP5R, except for a small delay in degradation of APP5R-CTF after 6 hours with 
lysosomal inhibitor bafilomycin A1. Thus, the increase in APP processing of APP3R and 
APP5R is not due to a disruption of APP degradation.  
4.2.4 APP lysine-to-arginine mutation affects exosomal APP-CTF 
content 
The disrupted ILV sorting of ubiquitin-deficient APP mutants led us to suspect that the 
APP content on exosomes may be diminished. Exosomes are small extracellular vesicles 
that are secreted from cells upon fusion of MVEs with the plasma membrane and release 
of ILVs contained within. Protein cargo sorted into ILVs can be released on exosomes, 
including APP and APP-CTFs (Perez-Gonzalez et al., 2012; Vingtdeux et al., 2007). To 
determine whether the disrupted ILV sorting of APP3RGFP and APP5RGFP mutants leads to 
a deficiency of APP3RGFP and APP5RGFP CTFs, we expressed the APP mutants in N2a 
cells, then collected and purified exosomes from the cell culture media (Figure 4.4). 
Compared to APPWT, both APP3RGFP and APP5RGFP CTFs are significantly reduced in 
exosomes, consistent with a reduced ability of these mutants to be sorted into ILVs. On 
the contrary, levels of Aβ associated with exosomes, as measured by ELISA, reveal a 
decrease in Aβ42/40 ratio for APP3RGFP and APP5RGFP, similar to secreted Aβ in the 
media.  
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4.2.5 PSEN2 cleaves missorted APP, leading to Aβ40 increase 
To test whether PSEN2 mediates the increased Aβ production in APP lysine-to-arginine 
mutants, we successfully knocked down PSEN2 in N2a cells via siRNA (Figure 4.5A,B), 
and measured levels of Aβ produced. We observed that the APP5RGFP-mediated increase 
in both secreted and intracellular Aβ40 (normalized to full-length APP) is abolished upon 
PSEN2 depletion (Figure 4.5C,D,E). Although Aβ40 levels in APP3RGFP-expressing cells 
trended in the same direction as APP3RGFP, the changes were not significant. There were 
no significant changes in levels of Aβ42 between control and PSEN2 siRNA-treated cells 
Collectively, these results corroborate our hypothesis that the higher Aβ40 levels 
measured in APP5R expressing cells are due to increased cleavage by PSEN2-containing 
γ-secretase complexes. Although Sannerud et al. presented data showing that PSEN1 
contributes more to extracellular Aβ secretion than PSEN2 (Sannerud et al., 2016), our 
data suggests that PSEN2-containing γ-secretase complexes on the endosomal limiting 
membrane cleave an additional pool of APP-CTF that accumulates when APP5RGFP fails 
to be sequestered in ILVs. Unexpectedly, the reduction in APP5R Aβ42/Aβ40 ratio was 
unchanged upon PSEN2 depletion, possibly because of other factors affecting the 
secretion of the less abundant Aβ42, such as the specific APH1 subunit, which has been 
shown to play a role in Aβ profile as well (Meckler & Checler, 2016).  
To confirm the specific role of PSEN2 in the increased secretion of APP5R Aβ40, we 
knocked down PSEN1 in N2a cells using siRNA, however, it led to a compensatory 
increase in PSEN2 of approximately 30% that was significant for APP5RGFP only, which 
complicated interpretation of any changes in levels of Aβ (Figure 4.6A,B). Compensation 
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of PSEN after depletion of one isoform has been described previously (Thinakaran et al., 
1997), however we did not see a significant increase in PSEN1 after PSEN2 knockdown. 
Nonetheless, we noted that PSEN1 depletion did abolish differences in Aβ40 levels 
between APPWTGFP and APP3RGFP/APP5RGFP, however the decrease was not significant 
between control and PSEN1 siRNA, as it was in PSEN2 depleted cells (Figure 4.6C,D). 
On the other hand, the increase in intracellular Aβ40 levels in APP5RGFP cells was 
unaffected by PSEN1 depletion (Figure 4.6E). Thus, our data suggests that the specific 
increase in Aβ40 exhibited by APP5RGFP is likely due mainly to cleavage of APP5RGFP by 
PSEN2-containing γ-secretase complexes subsequent to endosomal redistribution of the 
ubiquitin-deficient APP mutant (Figure 4.7). 
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4.3 Figures 
Figure 4.1. APP3RGFP and APP5R does not alter cell surface localization of APP.  
N2a cells expressing APPWTGFP, APP3RGFP, or APP5RGFP were bathed in biotin to label cell 
surface proteins, then immunoprecipitated with streptavidin. A) Representative Western 
blot of total cell lysate (total) and immunoprecipitated biotinylated protein (surface). B) 
Quantification of cell surface levels of APPGFP from Western blot. Values are expressed 
in arbitrary units (A.U.) relative to APPWTGFP alone. Values denote mean +/- SEM, n=6) 
and are non-significant as measured by one sample Student’s t-test. 
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Figure 4.2. APP3RGFP and APP5RGFP are localized on the periphery of the endosome.  
A) Representative confocal images of endosomes in N2a cells expressing APPWTGFP, 
APP3RGFP or APP5RGFP and Rab5Q79Lmcherry. Scale bar, 10uM. B) Quantification of APPGFP 
localization in the endosome by enumerating proportion of endosomes with GFP signal 
luminally to peripherally, per cell. Values denote mean +/- SEM, n=29-37 cells from 
three separate experiments) **P values<0.01, as measured by Student’s t-test. C) High 
resolution AIRY scan images of endosomes in N2a cells expressing APPWTGFP, APP3RGFP 
or APP5RGFP and Rab5Q79Lmcherry show ILV-like structures within endosomes expressing 
APPWTGFP. Scale bar, 10uM.  
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Figure 4.3. Time course of APP degradation is largely unchanged by APP3R and APP5R mutations.  
A) Representative Western blot of FL-APP, APP-CTF and tubulin at time points of 
degradation, in presence of cycloheximide and γ-secretase inhibitor XXI in N2a cells 
expressing APP. B) Quantification of FL-APP and APP-CTF Western blot, expressed as 
percent of untreated 0 time point. C) Representative Western blot of FL-APP, APP-CTF 
and tubulin at time points of degradation, in presence of cycloheximide, γ-secretase 
inhibitor XXI and bafilomycin A1 to inhibit lysosomal degradation in N2a cells 
expressing APP. D) Quantification of FL-APP and APP-CTF Western blot, expressed as 
percent of untreated 0 time point. Values denote mean +/- SEM, n=3-5 **P values<0.01, 
as measured by two way ANOVA with Bonferroni correction. 
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Figure 4.4. Exosomal content of APP-CTF is reduced in N2a cells expressing APP3RGFP and 
APP5RGFP.  
A) Representative Western blot of FL-APP (22C11 N-terminal marker), CTF-GFP (C-
terminal marker) and alix in the cell lysate and exosomes purified by ultracentrifugation 
of cell media from N2a cells expressing APP-GFP. Bands corresponding to exogenous 
APP-GFP, endogenous murine APP, and exogenous CTF-GFP and AICD-GFP are 
indicated by arrows. B) Quantification of CTF-GFP in exosomes isolated from cell 
culture media of N2a cells expressing APP-GFP. CTF-GFP levels are normalized to alix, 
a marker of exosomes, and expressed in arbitrary units (A.U.) relative to WT APP. 
Values denote mean +/- SEM, n=3 *P values<0.05, **P values<0.005, ***P 
values<0.001 as measured Student’s t-test. C) Aβ40 and Aβ42 associated with exosomes 
isolated from cell culture media of N2a cells expressing APP-GFP measured by ELISA. 
Values are expressed in arbitrary units (A.U.) relative to WT APP. Values denote mean 
+/- SEM, n=4.  
Karine Laulagnier 
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Figure 4.5. Increase in APP5RGFP Aβ40 abolished by presenilin-2 depletion.  
A) Representative Western blot of N2a cells treated with non-targeting (CTRL) or 
PSEN2 siRNA and expressing APPGFP. B) Quantification of Western blot for PSEN1 and 
PSEN2, and (C) full-length APP, normalized to actin D) Secreted Aβ measured by 
ELISA from culture media, normalized to levels of FL-APP. E) Intracellular Aβ 
measured by ELISA of cell lysate, adjusted to protein concentration and normalized to 
FL-APP. Values are relative compared to APPWT CTRL condition, and expressed in 
arbitrary units (A.U.) Values denote mean +/- SEM, n=10-13) *P values<0.05, **P 
values<0.005, ***P values<0.001 as measured by Student’s t-test
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Figure 4.6. Presenilin-1 knockdown leads to compensatory increase in presenilin-2.  
A) Representative Western blot of N2a cells treated with non-targeting (CTRL) or 
PSEN1 siRNA and expressing APPGFP. B) Quantification of Western blot for PSEN1 and 
PSEN2, and (C) full-length APP, normalized to actin D) Secreted Aβ measured by 
ELISA from culture media, normalized to levels of FL-APP. E) Intracellular Aβ40 (Aβ42 
below detection levels) measured by ELISA of cell lysate, adjusted to protein 
concentration and normalized to FL-APP. Values are relative compared to APPWT CTRL 
condition, and expressed in arbitrary units (A.U.) Values denote mean +/- SEM, n=10-
13) *P values<0.05, **P values<0.005, ***P values<0.001 as measured by Student’s t-
test 
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Figure 4.7. Model for PSEN2-mediated cleavage of missorted APP lysine-to-arginine mutant. 
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4.4 Discussion 
4.4.1 APP and ESCRT 
Endosomes have been subject to increasingly intense focus in understanding AD 
pathophysiology because subtle alterations in endosomal sorting can have important 
implications for the intracellular itinerary of APP and thus its amyloidogenic cleavage 
(Rajendran et al., 2008; Toh & Gleeson, 2016). We initially implicated APP as a cargo of 
the ESCRT pathway after an investigation into lipid changes in the AD brain and the 
discovery of a specific reduction in PI3P that was common to both FAD mouse models 
and human AD brains in areas associated with AD pathology (Chan et al., 2012; Morel et 
al., 2013). Endosomal PI3P recruits Hrs, a component of ESCRT-0 complex, via its 
FYVE domain. Although there are no known genetic mutations linking ESCRT to AD, a 
mutation of ESCRT-III component, charged multivesicular body protein 2B (CHMP2B), 
can cause frontotemporal dementia (Li et al., 2015; Urwin et al., 2009). Furthermore, 
neurons deficient in PI3P via Vps34 depletion undergo increased amyloidogenic 
processing and endosomal missorting (Morel et al., 2013). Depletion of ESCRT-0 
component Hrs led to a similar accumulation of APP on the endosomal membrane in 
HeLa cells, lending support to the hypothesis that the ESCRT pathway controls APP 
endosomal sorting. However, it remains unclear whether ESCRT disruption increases or 
decreases Aβ generation. Choy et al. showed that depletion of early ESCRT components 
(Hrs, Tsg101) in HEK293 cells led to a decrease in secreted Aβ40, while depletion of late 
ESCRT (CHMP, Vps34) components led to an increase in secreted Aβ40 (Choy et al., 
2012). Edgar et al. also identified APP and Aβ in ILVs of transgenic mice, and confirmed 
that Hrs depletion leads to a redistribution of APP to the limiting membrane of MVEs in 
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H4 cells, via EM. They also show that depletion of Hrs and Tsg101 leads to a decrease in 
secreted Aβ, but an increase in intracellular Aβ (Edgar et al., 2015). These studies 
apparently conflict with our work indicating that disruption of the Vps34/PI3P/ESCRT 
pathway causes increased amyloidogenic processing. However, we show that there are 
clear differential effects on Aβ species, and the above studies measure only Aβ40 (Choy 
et. al. 2012), or use a pan-Aβ-antibody (Edgar et. al., 2015). Furthermore, our studies 
confirm Aβ changes in primary neuronal cultures. ESCRT machinery is known to handle 
many protein cargos in cells, and disruption of these components could have 
consequences for APP-interactors. Finally, depletion of early ESCRT components may 
prevent formation of ILVs entirely, and thus secretion of exosomes, one of the ways in 
which Aβ is released extracellular (Malm et al., 2016). As opposed to altering levels of 
ESCRT components, we instead investigate the effects of APP lysine-to-arginine mutants 
that presumably cannot undergo sorting into ILVs via the ESCRT pathway. We 
hypothesized that disruption of a ubiquitin signal on APP would similarly interfere with 
the ability of ESCRT to recognize APP, and that the resulting accumulation of APP on 
the limiting membrane of the endosome leads to increased processing and Aβ generation. 
Indeed, we show that APP5R leads to a selective increase in APP metabolism, as 
described in the previous chapter. Consistent with the study by Edgar et al., we also show 
an accumulation of Aβ intracellularly. Our data suggest that APP is indeed a cargo of the 
ESCRT machinery, and disruption of ubiquitin signaling prevents normal endosomal 
sorting, leading to altered APP trafficking and processing. It is important to note that 
most cells still contain endosomes with luminal APP, suggesting that some APP or APP-
CTF can be sorted into ILVs via other mechanisms.  
	 93	
4.4.2 APP and Aβ in exosomes 
Deficiency of APP ubiquitination also impacts the exosomal content of APP, with 
implications for AD pathology. The role of exosomes in neurodegenerative disease is 
unclear, but some suggest that they may play a role in spread of pathology, by carrying 
misfolded proteins from one cell to another (Chivet et al., 2013; Kalani, Tyagi, & Tyagi, 
2014). As discussed in Chapter 1, Aβ can be found associated with neuronal exosomes, 
and along with APP-CTFs are increased in exosomes from AD brains (Perez-Gonzalez, 
2012; Rajendran et al., 2006, 2007). In fact, alterations in endosomal sorting can have an 
impact on exosome content. Disruption of the retromer is known to increase the amount 
of APP-CTFs secreted in exosomes (Sullivan et al., 2011). Exosomes may also represent 
a protective element, whereby neuronal exosomes with abundant glycophospholipids 
could capture extracellular Aβ and prevent subsequent synaptic or neuronal damage 
(Yuyama et al., 2015). The APP3RGFP and APP5RGFP mutants are not efficiently sorted to 
ILVs, and thus we see a reduction of APP-CTF on exosomes. Conceivably, this could 
contribute to the protective profile of the APP lysine-to-arginine mutants, by reducing 
spread of toxic APP metabolites. However, the role of exosomes in neurodegenerative 
disease is a growing field and it is difficult to make predictions at this early stage.  
4.4.3 γ-secretase composition and Aβ production 
As briefly discussed in Chapter 1, the contribution of different composition of γ-secretase 
complexes (based on inclusion of APH1A or B/C, and PSEN1 or 2) to localization or 
substrate specificity remains unknown. Understanding these factors could lead to 
development of therapeutics that target specific complexes, for instance a γ-secretase 
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inhibitor that could inhibit complexes that cleave APP, but not Notch. Furthermore, 
contribution of different γ-secretase complexes to secreted or intraneuronal Aβ could 
yield insights into how AD pathogenesis originates. With the alternate APH1A or B/C 
and PSEN1 or 2, there are four possible compositions of γ-secretase complex, which 
becomes more complex when alternative splicing of PSEN and APH are taken into 
account (Gu et al., 2003). PSEN1 has been much more extensively studied than PSEN2, 
mainly because the majority of FAD mutations occur in PSEN1, and PSEN1 KO is 
embryonic lethal, while PSEN2 KO mice shows no overt phenotype in mice (De Strooper 
& Gutiérrez, 2015). For these reasons, the role of PSEN2 in disease has been largely 
neglected until recent years.  
Only a few studies have investigated the effect of PSEN subunit on Aβ profile. Acx et al. 
studied the effect of cleavage of γ-secretase composition on C99 substrate in vitro and 
found that PSEN2 is less efficient in cleavage of Aβ peptides specifically in the Aβ48 
pathway, leading to less turnover of Aβ42 to Aβ38 (Acx et al., 2013). Meckler and 
Checler recently showed that PSEN1-containing complexes are delivered to the plasma 
membrane whereas PSEN2-containing complexes are targeted to trans-Golgi, recycling 
endosomes and late endosomes, and that PSEN2-containing complexes produced lower 
levels of Aβ40 and Aβ42 in vitro, with an increase or decrease in Aβ42/40 ratio 
dependent on the APH1 subunit (Meckler & Checler, 2014, 2016). In cells stably 
expressing either PSEN1 or PSEN2, Sannerud et al. showed that PSEN2 complexes were 
restricted to the late endosome/lysosome, and that PSEN2 favored accumulation of 
intracellular Aβ over extracellular. The Aβ profile was largely unchanged in cells 
expressing PSEN1 versus PSEN2, though the levels of Aβ42 were significantly increased 
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intracellularly upon introduction of a PSEN1 FAD mutation that exhibited cellular 
localization more similar to PSEN2 (Sannerud et al., 2016). Yonemura et al. confirm that 
Aβ secretion is depressed in cells stably expressing PSEN2 compared to PSEN1, and 
show that Aβ ratio is highly dependent on the APH subunit. Interestingly, they also report 
a slight preference for APP over Notch cleavage in certain PSEN2-containing γ-secretase 
complexes (Yonemura et al., 2016).  
In transgenic mice, intraneuronal Aβ accumulation coincides with synaptic dysfunction, 
and precedes amyloid plaque deposition (Friedrich et al., 2010; Gouras et al., 2010; Oddo 
et al., 2003). Sannerud et al. provided a link between intracellular Aβ and cleavage by 
PSEN2-containing γ-secretase complexes that are specifically localized to the late 
endosome/lysosome compartment. The authors show that PSEN2 is enriched on the 
limiting membrane of enlarged endosomes, reminiscent of the localization of APP5RGFP 
(Sannerud et al., 2016). We hypothesized that the APP5RGFP-induced increase in Aβ40 is 
caused by aberrant cleavage of APP5RGFP CTFs that accumulate on the endosomal 
membrane in proximity to PSEN2. Indeed, depletion of PSEN2 significantly decreases 
the elevated levels of Aβ40 seen in APP5RGFP, both extracellulary and intracellularly to 
levels of APPWTGFP. PSEN1 depletion also causes a trend towards reduction in secreted 
Aβ40, however, it was not significant, and is complicated by a ~30% in PSEN2 levels, 
suggesting that PSEN2 predominantly contributes to the Aβ40 increase. Although 
Sannerud et al. report an increase in the ratio of Aβ42/40 intracellularly due to PSEN2, 
we saw the most significant change in levels of Aβ40. We did not account for 
contribution of APH subunit to the γ-secretase complex composition, which has been 
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previously shown to affect the complex localization and Aβ profile (Acx et al., 2013; 
Meckler & Checler, 2014, 2016, Serneels et al., 2005, 2009, Yonemura et al., 2016).  
Clearly, we have much to learn regarding the contribution of different γ-secretase 
subunits to Aβ production. Inconsistencies in these studies could be due to differential 
effects in γ-secretase cleavage in vitro or in cells, especially since exogenous expression 
of PSEN could affect its trafficking. In our study, depletion of PSEN2 abolished the 
APP5RGFP-mediated increase in Aβ40, especially intracellularly, which we believe is 
consistent with available data thus far. We hypothesize that this effect is not due to a 
change in the ratio of Aβ mediated by PSEN2 cleavage, but instead due to cleavage of an 
additional pool of APP that accumulates on the endosomal membrane, with the normal γ-
secretase preference for Aβ production. 
 
5 Chapter 5 APP-L723P is an FAD mutant that has altered 
endosomal sorting 
5.1 Introduction 
Single mutations in APP that cause FAD near the BACE1-cleavage site lead to an 
increase in overall levels of Aβ. However, several families with EOAD have been found 
to harbor mutations near the γ-secretase site, in which case the ratio of Aβ42/40 is 
generally increased (De Jonghe et al., 2001). Gamma-secretase cleavage occurs on C99 
between APP residues 711 and 712 (Aβ40 cleavage) or 713 and 714 (Aβ42 cleavage). 
There are a cluster of APP FAD mutations in this area, as shown in Figure 5.1 (Van Dam 
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& De Deyn, 2011). In the juxtamembrane region, a few residues downstream from the γ-
secretase cleavage site, and adjacent to the three lysines that we previously identified to 
be important for APP ubiquitination, lies the site of the L723P (Australian) FAD 
mutation, termed APPLP. Although this mutation has not been extensively studied, the 
initial characterization reported an increase in the ratio of Aβ42/40 when expressed in 
CHO cells (Kwok et al., 2000). We chose to further study this mutant because of its 
proximity to the string of three lysines that are the site of the APP3RGFP mutant. We 
hypothesized that this mutation at this residue from leucine to the rigid proline group 
could interfere with post-translational modification at the neighboring lysines. Here we 
show that the APPLP mutation has a combined phenotype in terms of APP processing and 
trafficking. Specifically, it exhibits some elements of ubiquitin deficiency, such as 
increase in sAPPβ and endosomal redistribution, but is ultimately reminiscent of PSEN 
FAD mutations that inhibit γ-secretase processivity to increase the ratio of Aβ42/40. 
5.2 Results 
5.2.1 APPLP is redistributed to the endosomal membrane 
We hypothesized that the rigid proline group of the APPLPGFP  mutation might interfere 
with ubiquitin signaling at the APP3R site due to their proximity (Figure 5.2A). The 
APP3RGFP and APP5RGFP mutants undergo missorting from the endosomal lumen to the 
endosomal limiting in N2a cells. When APPLPGFP and Rab5Q79LmCherry are co-expressed in 
N2a cells, there is indeed a significant missorting of endosomal APP to the limiting 
membrane (Figure 5.2B,C), although the effect was smaller than APP3RGFP-induced 
missorting and there was much more variability in the cells expressing APPLPGFP. To 
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determine whether a decrease in ubiquitination could be detected for APPLPGFP, we co-
expressed the construct in N2a cells with UbK48RHA to exclude K48 polyubiquitination 
that is primarily a signal proteasomal degradation. After immunoprecipitating APP with 
an anti-GFP antibody, we could detect only a trend for a decrease in ubiquitination of 
APPLPGFP compared to APPWTGFP by Western blot (Figure 5.2D). 
5.2.2 APPLP mutation increases both secreted and intracellular 
Aβ42/40 ratio 
To study the effects of the APPLP mutation on APP metabolism, we expressed APPLPGFP 
in N2a cells, and collected cell lysate and media to measure APP metabolites by Western 
blot or ELISA. Similar to the previous report in CHO cells (Kwok et al., 2000), the levels 
of Aβ42, normalized to full-length APP, were dramatically increased in cell media, ~23 
fold higher than APPWTGFP, and no change in normalized Aβ40, leading to an increase in 
Aβ42/40 ratio of ~19 fold. In addition, there was a 39.1% decrease in full-length APP, 
and an 82.9% increase in sAPPβ, with no change in sAPPα or levels of CTF. Intracellular 
levels of Aβ42 also trended towards an increase in N2a cells expressing APPLPGFP, with a 
significant increase in the ratio of Aβ42/40 (Figure 5.3).  
To confirm these alterations in APP metabolism in primary neuronal cultures, we 
expressed APPLPGFP in murine cortical neuronal cultures via lentivirus at DIV7. Similar 
to findings from N2a cells, the APPLP mutant generated ~22 fold more Aβ42, normalized 
to full-length APP, leading to an ~18 fold increase in the Aβ42/40 ratio. Again consistent 
with N2a cells, the APPLPGFP expressing neurons produced 84.6% more sAPPβ into the 
media, and no change in sAPPα (Figure 5.3). The increase in sAPPβ would suggest an 
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increase in BACE1 cleavage, which is surprising considering that the mutation is distant 
from the APP BACE1 cleavage site and the increase in Aβ42/40 ratio is more consistent 
with an alteration in γ-secretase cleavage. Although we could not detect APP-CTFs at a 
basal level, after 24 hours of γ-secretase inhibitor XXI treatment, a band appeared on 
Western blot at the expected size. In cells expressing APPLPGFP and treated with γ-
secretase inhibitor XXI, there was a 47.9% decrease in CTFLPGFP, normalized to full-
length APP. This is consistent with PSEN FAD mutations that lead to a loss of function 
of γ-secretase cleavage. Thus, we hypothesize that the APPLP mutation not only shows 
features of loss of γ-secretase processivity, but also disrupts the trafficking of APP, such 
that the interaction between APP and BACE1 is increased.  
5.2.3 APPLP alters interaction with γ-secretase to increase the ratio of 
Aβ42/40  
Because of the close proximity of the APP L723P site to the γ-secretase cleavage site, we 
hypothesized that the phenotype of the APPLPGFP mutant may be partially due to a change 
in processivity by γ-secretase. We incubated C99LP substrate in vitro with purified γ-
secretase membranes, and measured the levels of Aβ40 and Aβ42 produced. Compared to 
C99WT, there was a trend towards an increase in Aβ42, with no change in Aβ40, 
suggesting that APPLP mutation changes the structure of APP and its interaction with γ-
secretase, shifting the Aβ profile towards Aβ42 (Figure 5.6).  
	 100	
5.2.4 APPLP exosomal content is unchanged, but degradation is 
delayed 
As discussed in the previous chapter, protein cargo in ILVs can undergo multiple fates, 
including secretion extracellularly as exosomes or lysosomal degradation. To determine 
the downstream effects of APPLP endosomal redistribution, we first measured the 
exosomal content of APPLP in exosomes isolated from N2a cell culture media. Unlike the 
decrease in exosomal APP-CTFs that we noted for APP5RGFP, there was a trend towards 
an increase in APPLP CTFs in exosomes, but no significant change (Figure 5.7). On the 
other hand, the lysosomal degradation of APPLP was significantly altered, as measured by 
levels of full-length APP and APP-CTFs in N2a cells, at five time points after the initial 
application of protein synthesis inhibitor cycloheximide (Figure 5.8). Gamma-secretase 
inhibitor XXI was also applied, to specifically identify changes in non-secretase 
degradation. The APPLP mutation led to a delay in degradation of both full-length APP 
and APP-CTFs compared to APPWT at 1 and 2 hours after the addition of cycloheximide. 
Interestingly, there was less impairment in degradation of APPLP when lysosomal 
inhibitor bafilomycin A1 was added, especially for APP-CTFs, which no longer showed 
any significant difference between APPWT and APPLP.  
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5.3 Figures 
Figure 5.1. Portion of APP showing familial AD mutations clustered around secretase cleavage sites.  
Red portion indicates Aβ peptide region and brown box indicates transmembrane domain. 
Note large number of FAD APP mutations around γ-secretase cleavage site, and the 
Australian mutation slightly downstream (Van Dam and De Deyn 2006). 
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Figure 5.2. APPLPGFP is redistributed to the endosome periphery, but only trends towards ubiquitin 
defiency ..  
A) hAPP COOH-terminus domain showing Australian L723P mutation in relation to 5 
lysine residues that are potential sites of ubiquitination. Aβ40 and Aβ42 arrows indicate 
sites of γ-secretase cleavage. B) Representative confocal images of endosomes in N2a 
cells expressing APPWTGFP or APPLPGFP and Rab5Q79Lmcherry. Scale bar, 10uM. B) 
Quantification of APPGFP localization in the endosome by enumerating proportion of 
endosomes with GFP signal luminally to peripherally, per cell. Values denote mean +/- 
SEM, n=29-37 cells from three separate experiments *P value<0.05, as measured by 
Student’s t-test. C) Quantification of ubiquitination of APPLPGFP compared to APPWTGFP 
after co-expression with UbK48RHA and immunoprecipitation with anti-GFP. Value 
expressed relative to APPWTGFP and non-significant by one-sample Student’s t-test. 
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Figure 5.3. APPLPGFP leads to an increase in secreted and intracellular Aβ42 in N2a cells .  
A) Representative Western blot of full-length APPGFP and actin from cell lysate and 
sAPPα from cell media of N2a cells expressing APPWTGFP and APPLPGFP lysine-to-
arginine mutants. B) Quantification of full-length APPGFP and sAPPα from Western blot, 
and quantification of Aβ40, Aβ42 and sAPPβ by ELISA of cell culture media. Full-length 
APPGFP is normalized to actin loading control and sAPPα, sAPPβ, Aβ40 and Aβ42 are 
normalized to APPGFP. C) Intracellular Aβ40 and Aβ42 levels measured by ELISA of cell 
lysate from N2a cells expressing APPWTGFP or APPLPGFP, normalized to full-length APP 
measured by Western blot. All are expressed in arbitrary units (A.U.) relative to 
APPWTGFP. Values denote mean +/- SEM, n=5-7 *P values<0.05, **P values<0.005,  as 
measured by one sample Student’s t-test. 
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Figure 5.4. APPLPGFP expression produces a dramatic increase in AB42 in primary neurons.  
APPWTGFP or APPLPGFP was expressed in primary murine cortical neurons via lentivirus at 
DIV 7, and cell lysate and culture media was harvested at DIV 14. Gamma-secretase 
inhibitor XXI was applied at 2uM to indicated samples, for 24 hours before harvest A) 
Representative Western blot of full-length APPGFP and synaptotagmin from cell lysate 
and sAPPα from cell media. B) Quantification of full-length APPGFP and sAPPα from 
Western blot, and quantification of sAPPβ by ELISA of cell culture media. Full-length 
APPGFP is normalized to synaptotagmin loading control and sAPPα and sAPPβ are 
normalized to APPGFP. C) Quantification of Aβ40 and Aβ42 levels measured by ELISA 
and normalized to full-length APP, and ratio of Aβ42/ Aβ40. D) Quantification of APP-
CTFGFP, normalized to full-length APP in cells treated with γ-secretase inhibitor XXI. All 
are expressed in arbitrary units (A.U.) relative to APPWTGFP. Values denote mean +/- 
SEM. Number in bar refers to number of samples in 4 separate dissections (3 dissections 






Figure 5.5. APPLP mutation alters interaction with γ-secretase in vitro.  
Levels of Aβ40 and Aβ42 from in vitro γ secretase assay. Purified APP C99 substrate is 
incubated with purified γ-secretase membranes and resultant Aβ levels are measured via 
ELISA. Aβ levels are expressed in arbitrary units (A.U.) relative to WT APP C99. Values 
denote mean +/- SEM, n=3 *P values<0.05, as measured by Student’s t-test. 







Figure 5.6. Exosomal content of APP-CTF is unchanged in N2a cells expressing APPLPGFP.  
A) Representative Western blot of FL-APP (22C11 N-terminal marker), CTF-GFP (C-
terminal marker) and alix in the cell lysate and exosomes purified by ultracentrifugation 
of cell media from N2a cells expressing APP-GFP. Bands corresponding to exogenous 
APP-GFP, endogenous murine APP, and exogenous CTF-GFP and AICD-GFP are 
indicated by arrows. B) Quantification of CTF-GFP in exosomes isolated from cell 
culture media of N2a cells expressing APP-GFP. CTF-GFP levels are normalized to alix, 
a marker of exosomes, and expressed in arbitrary units (A.U.) relative to WT APP. 
Values are expressed in arbitrary units (A.U.) relative to WT APP. Values denote mean 




Figure 5.7. Degradation of APPLP is delayed.  
Representative Western blot of FL-APP, APP-CTF and tubulin at time points of 
degradation, in presence of cycloheximide and γ-secretase inhibitor XXI in N2a cells 
expressing APP. B) Quantification of FL-APP and APP-CTF Western blot, expressed as 
percent of untreated 0 time point. C) Representative Western blot of FL-APP, APP-CTF 
and tubulin at time points of degradation, in presence of cycloheximide, γ-secretase 
inhibitor XXI and bafilomycin A1 to inhibit lysosomal degradation in N2a cells 
expressing APP. D) Quantification of FL-APP and APP-CTF Western blot, expressed as 
percent of untreated 0 time point. Values denote mean +/- SEM, n=3-5 ***P values<0.01, 
as measured by two way ANOVA with Bonferroni correction. 
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5.4 Discussion 
Many PSEN1 or PSEN2 mutations lead to a reduction in proteolytic activity of the γ-
secretase complex, which led to the theory that some instances of EOAD are due to a loss 
of function of presenilin (Wolfe, 2012). In these cases, there is not an increase in Aβ 
generation, but in fact an increase in the ratio of Aβ production that is skewed towards 
the longer, more aggregate prone species. Several inconsistencies in this theory had to be 
addressed. First of all, conditional knockouts of PSEN1 and PSEN2 lead to 
neurodegeneration and memory deficits, but not to Aβ deposition. Secondly, most FAD 
mutants discovered thus far are autosomal dominant, and none lead to a loss of presenilin 
or truncation, suggesting that haploinsufficiency does not cause AD (Wolfe, 2012). These 
data would suggest that presenilin FAD mutations are due to a gain of toxic function. 
However, in cell lines expressing PSEN FAD mutants, there was an increase in the 
Aβ42/40 ratio, in some instances due to a loss of Aβ40, and an accumulation of APP-
CTFs, lending support to the notion that γ-secretase complexes containing certain PSEN 
FAD mutations are indeed less efficient (Bentahir et al., 2006; Kumar-Singh et al., 2006). 
These seemingly conflicting views were reconciled by proposing that PSEN FAD 
mutations are due to a loss of function specifically of γ-secretase processivity (Quintero-
Monzon et al., 2011). Thus, the initial ε-cleavage of γ-secretase may or may not be 
affected by the PSEN FAD mutation, but the second γ-cleavage is less efficient, leading 
to the production of longer Aβ species. Here we show that APPLP exhibits an Aβ profile 
and delay in degradation consistent with a similar loss of processivity, as well as 
mistrafficking in the endosome that leads to an increase in BACE1 cleavage.  
	 109	
5.4.1 The APPLP mutation has combined trafficking and γ-secretase 
interaction defects 
Despite being unable to show a significant decrease in ubiquitination of the APPLPGFP 
mutant in N2a cells, there was still a redistribution of APPLPGFP from the endosomal 
lumen to the limiting membrane, possibly due to an obstruction in ubiquitin signaling of 
the neighboring triple lysine site. Alternatively, the rigid proline group in the 
juxtamembrane region of the APPLPGFP mutation could interfere with binding of other 
effectors to the APP C-terminal domain. In any case, the APPLPGFP mutation does 
undergo some degree of endosomal missorting, which could cause an increase in the 
interaction with BACE1 and explain the significant increase in sAPPβ noted in both N2a 
cells and primary neurons.  
In all other phenotypes that we studied, the APPLP mutant exhibited the opposite 
phenotype from the APP3R and APP5R mutants. Although all lead to an increase in Aβ 
generation compared to APPWTGFP, APPLPGFP produced a dramatic increase in Aβ42 and 
thus in the Aβ42/40 ratio, consistent with its discovery as an FAD mutation. Unlike 
APP5RGFP, the APPLPGFP mutant accumulated less APP-CTF upon γ-secretase inhibition 
in neurons. These APP processing phenotypes are indicative of a less efficient γ-secretase 
cleavage of APPLP, similar to PSEN FAD mutations. Indeed, the in vitro γ-secretase 
assay shows a significant increase in Aβ42 production in the absence of changes in 
cellular trafficking, which is reminiscent of PSEN1 mutations that have been studied in 
similar experiments (Fernandez et al., 2014). Of particular interest, APPLP showed a 
significant delay in degradation, but no change in exosomal content. The degradation 
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delay was decreased by addition of proton-pump inhibitor bafilomycin A1 to inhibit 
lysosomal degradation. This is consistent with the accumulation of APPLP on the limiting 
membrane of the endosome, where it is less likely to be affected by lysosomal inhibition 
than the APPWT present on ILVs. It remains unclear why there is a differential effect of 
degradation and exosomal content of the APPLP mutant vs. the APP3R and APP5R 
mutants. Although both appear to be deficient on ILVs, they are not completely absent. 
Different MVEs or different pools of ILVs may be sorted towards different fates, 
however, we do not yet know the signals that regulate such sorting (Budnik et al., 2016). 
Furthermore, some APP could also be sorted into ILVs by ubiquitin-independent 
pathways. Although the APPLP mutant shares the endosomal sorting phenotype of the 
“protective” lysine-to-arginine mutants, the change in γ-secretase interaction takes 
precedence and trumps any potential beneficial effect, leading to a dramatic increase in 
the Aβ42/40 ratio. 
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6 Chapter 6: Materials and methods 
Cell transfection and lentivirus production 
HEK-293T and N2a cells were grown at 37°C in a 5% humidified CO2 incubator in 
DMEM (Invitrogen) and 10% FBS (Life Technologies). After 24 hours of plating, cells 
were transfected with DNA using Lipofectamine 2000 or 3000 (Invitrogen) or JetPEI 
(VWR) for 24-48 hours via manufacturer’s directions. Cortical neurons were obtained 
from P0 mice brains, as described previously (Morel et al., 2013) Briefly, cortices were 
separated from brain and dissociated in 2.5% trypsin (Life Technologies). Neurons were 
plated on polyornithine (Sigma Aldrich) coated six-well plates, and were incubated with 
MEM (Invitrogen) with 10% FBS. After 5 hours, neurons were transferred into serum-
free Neurobasal medium (Life Technologies) supplemented with B27 (Invitrogen) + 
Glutamax (Gibco) and cultured for 7 days in vitro (DIV). Neurons were infected with 
lentivirus after 7 DIV, and were cultured up to 14 days. Where indicated, γ-secretase 
inhibitor was applied 24 hours before cell harvest. Lentiviruses were generated by 
transfecting lentiviral vectors (APPGFPWT, APPGFP3R, APPGFP5R) into HEK-293T cells 
using Lipofectamine LTX (Invitrogen). A pPACKH1 packaging mix (System 
Biosciences) was added to the transfection reagents according to the manufacturer’s 
instructions. The medium was collected 48 and 72 h after transfection, passed through a 
45-nm filter and applied at 1:4 ratio to media. 
Antibodies and reagents 
The antibody against PSEN1 was a kind gift from James J. Lah (Emory University) and  
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Tae Wan Kim (Columbia University). APP antibodies used were 6E10 (Covance SIG-
39300), C1/6.1 (BioLegend 802801), 22C11 (MIllipore MAΒ348), and CT-20 (Millipore 
171610). Other antibodies were obtained from the following sources: mouse antibody to 
GFP (Roche mouse 7.1 and 13.1 mix 11814460001) and mouse antibody to GFP 
(Invitrogen A6455), rabbit antibody to RFP (Rockland 600401379), mouse antibody to 
ubiquitin (Santa Cruz P4D1 sc-8017), mouse antibody to synaptotagmin (Synaptic 
Systems 105011), mouse antibody to pan-actin (Novus Biologicals NB600-535), mouse 
antibody to α-tubulin (Sigma T6074), rabbit antibody to alix (Covalab pAB0204), rabbit 
antibody to PSEN2 (Abcam EP1515Y) and rabbit antibody to USP5 (Proteintech 10473-
1-AP). Reagents used were bafilomycin A1 (50nM Wako 023-11641), γ-secretase 
inhibitor XXI Compound E (2µM EMD Millipore), cycloheximide (100ug/mL Sigma 
C4859), A/C heterodimerizer (2.5µM Clontech 635057), N-ethylmaleimide (10mM 
Sigma E3876) and 1,10-phenanthroline (4mM Sigma 131377). 
Plasmids 
Plasmids were kindly provided by the following sources: Ub73P-mcherry from Clarissa 
Waites (Columbia University), pET21bC100Flag backbone for C99 constructs used in in 
vitro γ-secretase assay from Michael Wolfe (Harvard University). mCherry 
Rab5CA(Q79L) was a gift from Sergio Grinstein (Addgene plasmid # 35138) 
(Bohdanowicz et al., 2012).  
The APPGFP lysine-to-arginine plasmids were generated by QuikChange II XL site-
directed mutagenesis (Agilent) following manufacturer’s instructions on base plasmids 
APPGFPWT or APPGFP 3R pEGFP-N3 plasmids (see Morel et. al., 2013) with the following 
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K725R APPWTGFP 5’ 
CACCTTGGTGATGCTGAAGAGGAAACAGTACACATCC
ATTC 3’ 
K726R APPWTGFP 5’ 
CACCTTGGTGATGCTGAAGAAGAGACAGTACACATCC
ATTC 3’ 
K751R APPWTGFP 5’ 
GAGCGCCACCTGTCCAGAATGCAGCAGAACGGCTAC 
3’ 




























Human APPGFP lentiviruses were generated by excising GFP with corresponding APP 
mutations from pEGFP-N3 with NheI/NotI (New England Biolabs) and ligating the 
cDNAs into pCDH-CMV-MCSr (System Biosciences) with T4 DNA ligase (New 
England Biolabs.  
Human APP plasmids were constructed by excising GFP from APPGFP pEGFP-N3 with 
corresponding APP mutations using BsrGI/SalI (New England Biolabs), followed by 
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DNA end blunting with T4 DNA polymerase (New England Biolabs) and blunt end 
ligation with T4 DNA ligase (New England Biolabs). 
Human APP C100-FLAG plasmids were generated by PCR amplification of APPGFP 
pEGFP-N3 vectors with respective APP mutations using forward primer 5’ 
ACAAAGCTTCTACTTATCGTCATCGTCCTTGTAATCGTTCTGCATCTGCTCAA
AGAACTT 3’ and reverse primer 5’ 
ATATCCTGAGTCATGTCGGAATTCTGCATCCATATGGACGAA 3’ followed by 
digestion of AKp-3 pET21bC100Flag (kind gift from Michael Wolfe) and PCR fragment 
with NdeI/HindIII (New England Biolabs) and ligation with T4 DNA ligase (New 
England Biolabs). 
Human APP-DmrA-RFP plasmids were generated by PCR amplification of the DmrA-
DmrA-mRFP fragment from pHet-Mem1-mRFP (pC4M-F2E-mRFP) with forward 
primer 5’ TAATGA GTCGAC GGA GTG CAG GTG GAA ACC ATC 3’ and reverse 
primer 5’ ACG ACG TAC CAG ACT ACG CAT TGTACA GTC GAG 3’ followed by 
digest of PCR fragment and APPGFP pEGFP-N3 with BsrGI/SalI (New England Biolabs) 
and ligation with T4 DNA ligase (New England Biolabs).  
siRNA 
Control siRNA was ON-TARGETplus Non-targeting siRNA #1 (GE-Dharmacon D-
001810-01-05), siRNA against Psen1 was ON-TARGET plus Mouse Psen1 (19164) 
siRNA – SMARTpool (GE-Dharmacon L-048761-01-0005), siRNA against Psen2 was 
ON-TARGET plus Mouse Psen2 (19164) siRNA – (GE-Dharmacon J-051123-10 and J-
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051123-12), and siRNA against Usp5 was ON-TARGET plus Mouse Usp5 (22225) 
siRNA – SMARTpool (GE-Dharmacon L-046492-01-0005). All siRNA was applied to 
N2a cells in 6-well plates via lipofectamine 3000 following manufacturer’s directions, at 
a concentration of 25nM. Cells and culture media were harvested after 3 days.  
Fluorescence microscopy 
For immunofluorescence experiments, cells grown on glass coverslips were washed once 
with HBSS (Gibco) and fixed with 4% paraformaldehyde (Electron Microscopy 
Sciences) for 20 min at room temperature. Cells were then washed twice in PBS (Boston 
Bioproducts) and permeabilized with a buffer containing saponin (Acros) 0.05%, BSA 
5% in PBS for 45 min at 37 °C. They were then incubated with primary antibodies diluted 
in the buffer for 1 h at room temperature, washed in buffer three times, incubated with 
fluorescent secondary antibodies (Invitrogen) diluted in buffer for 1 h at room 
temperature and washed again three times in buffer. Cells were finally washed once with 
PBS and coverslips were mounted in Vectashield mounting medium (Vectorlabs). Images 
were acquired by confocal laser scanning microscopy (Zeiss LSM 700 and 800) and 
analysed with Zeiss Zen and imageJ softwares. 
Protein biochemistry and immunoblotting 
To detect ubiquitinated APP, HEK293T cells were transiently transfected with human 
APPGFP and Ub48R-HA and then lysed for 30 min at 4°C in IP buffer (0.5% NP-40, 
500mM Tris–HCl, pH 7.4, 20mM EDTA, 10mM NaF, and a cocktail of protease and 
phosphatase inhibitors (Roche diagnostics)), centrifuged for 15min at 13,000rpm. 
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Supernatants were diluted to equal concentration and precleared with protein G sepharose 
beads (GE) before an overnight incubation at 4°C with 4 ug anti-GFP mAβ and 
subsequent 2h incubation at 4°C with protein G sepharose beads. After extensively 
washing the beads with IP buffer, proteins were eluted, separated on a 4-12% Bis–Tris 
gel (Invitrogen) and transferred by iBlot (Invitrogen) on a nitrocellulose membrane. 
Separate membranes were probed with anti-ubiquitin or anti-GFP antibodies. Images 
were acquired via the LAS4000 imager (GE Healthcare) and quantification was done 
using Image J. For all other immunoblots, cells were lysed for 30min at 4°C in 
ThermoFisher RIPA buffer or Pierce IP buffer with protease and phosphatase inhibitor 
cocktails, centrifuged for 15 min at 13000rpm, and proteins in the supernatant were 
processed for SDS-PAGE and immunoblotting. Tricine 10-20% gels were used for 
experiments measuring APP CTFs. For analysis of exosomes and lysates by Western-
blot, exosomes secreted by 18.10e6 N2a cells (2 dishes of 70cm2, ~28ug of protein) were 
loaded in parallel to 70ug of protein lysates i.e. 2% of a total dish. 8% acrylamide glycine 
gels and electrophoresis in glycine buffer were performed to detect APPGFP, CTFGFP, and 
Alix.  Semi-dry transfer of proteins was done on 0.45µm PVDF membranes (Millipore) 
during 1h. Membranes were blocked in 3% skimmed milk in Tris-buffered saline with 
0.01% tween (TBS-tween) and incubated with primary antibodies in the blocking 
solution during 1h at room temperature or overnight at 4°C. HRP-bound secondary 
antibodies were diluted 1/15000 in TBS-Tween and incubated 1h on membranes at room 
temperature. Detection reagent was home made using a mix of 50% 250mM luminol and 
50% of 90mM coumaric acid and 0.015% H2O2 mixed extemporarily.  
Purification of exosomes from N2a cells 
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Exosomes were isolated as described in Villette et. al. 2015 in Mov cells. Exosome-free 
medium was made by ultracentrifugating complete culture medium at 150000xg during 
18h followed by sterilization through 0.2µm filters. 24h after plating, N2a cells were 
transfected and 24h later complete medium was replaced by exosome-free medium. Cell 
supernatant was collected after 20h of secretion and exosomes were purified by 
differential utracentrifugation protocol : 2000 x g, 10min at 4°C followed by 20 000xg 
30min at 4°C. Supernatants were filtered through 0.22µm Millex GV PVDF filter 
(Millipore) and finally centrifuged at 110000 x g, 1h30 at 4°C in SW41 or SW32 rotors. 
110000 X g pellets were resuspended either in sample buffer (2% SDS , 2.5% β-
mercaptoethanol, 125mM Tris-HCl pH6.8, 10% glycerol, 2.5% bromophenol blue) for 
Western-blot analysis or in lysis buffer (20mM Tris, 150mM NaCl, 1mM EDTA,  1% 
NP40, anti-protease mix from Roche) for anti-Aβ42, Aβ40 ELISA, protein dosage. When 
cell lysate was required, neurons or N2a cells were lysed in 1mL of lysis buffer during 
30min on ice and centrifuged at 20000xg, 10min at 4°C before use. 
Gamma secretase assay 
APPWT and APP5R C100-FLAG substrates (APP C99 with an N-terminal methionine and 
a C-terminal FLAG tag) were expressed in BL21-CodonPlus cells (Agilent) and purified 
using M2 anti-FLAG affinity gel (Sigma-Aldrich). The protein concentration in each 
C100-FLAG preparation was measured by BCA assay (Pierce). 1 µM substrate was 
incubated with purified γ-secretase in assay buffer (50 mM HEPES pH7.0 and 150 mM 
NaCl) with 0.1% phosphatidylcholine, 0.025% phosphatidylethanolamine, 0.00625% 
cholesterol, and 0.25% CHAPSO for 1 hour at 37°C. Aβ40 and Aβ42 generated in the 
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reactions were quantified using specific ELISAs (Invitrogen).   
Chemically-induced ubiquitination assay 
Clontech idimerize inducible heterodimerizer system was modified for the experiment. 
N2a cells at 60% confluence in 10cm plates were transfected with APPWTDmrA-RFP or 
APP5RDmrA-RFP alone or co-transfected with UbDmrC. Culture media was changed 24 hours 
after transfection, and ethanol or 2.5µM A/C heterodimerizer dissolved in ethanol were 
added as indicated. Culture media and cells were harvested as described above, 12 hours 
after media change, to measure Aβ40 and Aβ42 levels via ELISA. 
Cell surface biotinylation assay 
To measure proportion of APP localized to the cell surface, we used the contents of the 
Pierce™ Cell Surface Protein Isolation Kit (Thermofisher 89881). N2a cells 
expressing APPGFP in a 6-well plate were incubated with biotin and then quenched, 
according to manufacturer’s directions. Instead of using provided tubes, 
NeutrAvidin agarose beads were added directly to equal concentrations of 
sonicated protein lysate (as measured by BCA assay (Pierce)), extensively washed 
and eluted by boiling in LDS buffer. Samples of total protein (before addition of 




APPGFP was immunoprecipitated from N2a cells transfected with APPGFP 
constructs, as described above. A large concentration of starting material (3000ug) 
was used, from three 10cm tissue culture plates, and N-ethylmaleimide and 1,10-
phenanthroline was added to the lysis buffer and all subsequent wash buffers. 5% 
of immunoprecipitate was subjected to SDS-PAGE and stained with silver stain 
(Sigma) with various concentrations of BSA to approximate protein concentration, 
another 5% for Western blot to identify bands corresponding to APPGFP and the 
remaining 90% was separated by SDS-PAGE and stained with SimplyBlue 
SafeStein (ThermoFisher). Gel regions were excised, trypsin digested and analysed 
by mass spectrometry, as described previously (Phu et al., 2011). 
Quantification of APL-1:GFP in C. elegans 
Strains of C. elegans with enhanced RNAi in the nervous system against a specific 
DUB were crossed to another strain that expresses APL-1-GFP under a GABA-ergic 
promoter. DUB RNAi strains were chosen from a genome-wide library as described in 
Kowalski et al., 2011. Fluorescent imaging in C. elegans and quantification of GFP levels 
in neurons is also as described (Kowalski, Dahlberg, & Juo, 2011). 
Enzyme-linked immunosorbent assays 
To measure human Aβ40 and Aβ42, or human sAPPβ from cell culture of N2a cells 
transfected with APPGFP, media was changed 24 hours before cell harvest. For cortical 
neuronal cultures expressing APPGFP, media was collected at DIV14, 7 days after 
application of lentivirus. Media was collected at 4°C and supplemented with 0.25 mg/ml 
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Pefabloc SC 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride (Fuka Analytical) 
and centrifuged at low speed to remove cell debris for 5 min. Intracellular Aβ40 and 
Aβ42 was measured from cells lysed for 30 min in 20 mM Tris pH7.4, 150 mM NaCl, 
1mM EDTA, 1% NP40 and cocktails of protease and phosphatase inhibitors at 4°C, then 
centrifuged at 13,000 rpm for 15 min. ThermoFisher (Invitrogen) ELISA kits were used 
for Aβ40 and Aβ42 measurements from cell culture media and in vitro γ-secretase assay. 
Mesoplex V-PLEX Aβ Peptide Panel 1 (4G8) (Meso Scale Discovery) kits were used for 
Aβ40 and Aβ42 measurements from cell lysate and exosomes, where an equal 
concentration of protein, measured by BCA assay (Pierce) was loaded for each sample. 
Covance kits were used for measurements of sAPPβ from cell culture media. All kits 
were used according to the manufacturer’s instructions.  
Statistics 
Statistical analysis was performed using GraphPad Prism software (version 6). All mutant 
samples were compared to WT using two-tailed Student’s t-test (for the comparison of 
two averages), and the one-sample t-test (for the comparison of one average to a 
normalized value where variability is lost). A one-tailed t-test was exceptionally used in 
figure 1 because of previous findings in Morel et al., 2013. Two way ANOVA was used 
for APP degradation experiments.  
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7 Concluding Remarks and Future Directions 
AD afflicts a growing number of people every year, but clinical trials thus far have been 
disappointing. Elucidating the endosomal trafficking itinerary of APP is fundamental to 
understanding how endosomal dysfunction contributes to the pathophysiology of AD. 
The recognition of the endosome as a crucial decision point in the amyloidogenic 
pathway opens the door for discovery of much needed novel therapeutic targets. The long 
prodromal phase that precedes symptomatic development in AD makes drug 
development particularly difficult, because any effective Aβ-reducing therapies or 
prophylaxes will likely need to be taken for years, if not decades. As such, it is even more 
vital that we define the molecular underpinnings of APP metabolism, to predict the long 
term changes that might evolve from altering these pathways. In this dissertation, we 
sought to characterize APP ubiquitination and determine how deficiency of this signal 
can change APP metabolism, as well as the downstream trafficking endosomal trafficking 
defects that arise. Here, we will discuss some of the most pressing questions that stem 
from our results. 
One of the largest gaps in our current knowledge surrounding APP ubiquitination is the 
identity of APP E3 ubiquitin ligases and deubiquitinases. There are likely more than one 
of each that can act on APP in distinct temporal or spatial compartments, or that act on 
different fragments containing the APP C-terminal region (e.g. full-length APP, APP-
CTF, AICD) for various purposes. In our study, we measure only full-length APP 
ubiquitination, and we do not distinguish endosomal trafficking of full-length APP or 
APP-CTF. A recent screen of ubiquitin-proteasome machinery that interacts with the 
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APP cytosolic region lays some groundwork for identification of E3 ubiquitin ligases or 
deubiquitinase, but these candidates will need to be confirmed with further studies (Del 
Prete et al., 2016). Indeed, our screen of APP deubiquitinases in C. elegans matched two 
deubiquitinases uncovered in this screen of APP interactors. Our preliminary evidence of 
USP5 depletion shows an effect on Aβ levels, but much more work is necessary to 
determine a direct interaction with APP. One of the challenges that we faced here was 
enriching for sufficient levels of ubiquitinated APP without the use of inhibitors or 
overexpression of ubiquitin mutants, which can alter the cellular ubiquitome. 
Identification of an E3 ubiquitin ligase or deubiquitinase may allow for upregulation of 
ubiquitinated APP and aid in further characterization, which will enable further 
understanding of these pathways. 
A promising area of new AD therapeutics are the γ-secretase modulators, which aim to 
curtail the production of longer species of Aβ, such as Aβ42. While some γ-secretase 
modulators simply decrease Aβ42 levels, others also increase levels of C-terminally 
truncated Aβ species. While there is data to suggest that increasing the levels of Aβ40 
can be protective in terms of preventing oligomeric assembly, amyloid deposition and 
cellular toxicity induced by Aβ42 (as described in Chapter 3), there are several questions 
yet to be answered. Firstly, we do not know whether Aβ40 can interfere with Aβ42 
assembly once it has already begun to aggregate. Increasing Aβ40 could be a 
prophylactic treatment, but that would require extremely early diagnosis of patients with 
presymptomatic AD, and faithful adherence to treatments, not to mention potential 
unknown side effects of decades-long treatment. Secondly, and perhaps more worrisome, 
is the effect of Aβ40 increase on the deposition of amyloid in CAA, which shows a 
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predominance of Aβ40 over Aβ42. Certain mutations in the Aβ sequence, such as the 
Dutch, Iowa, Flemish and Italian FAD mutations, lead to CAA, in which vascular 
amyloid deposits are largely composed of Aβ40. Some evidence shows that these 
mutations can be amyloid seeds in the microvasculature that drive assembly of higher 
order amyloid aggregates in vivo (Xu et al., 2016). Conversely, others show that 
increasing Aβ40 in vivo can prevent formation of vascular amyloid pathology in a 
transgenic mouse model of AD (Kim et al., 2007). It remains unclear whether non-
mutated Aβ can seed amyloid deposition, and what will be the effect of increasing Aβ40 
generation once some Aβ pathology has already formed. The APP5R mutant might help to 
answer some of these questions, since it has a selective increase in Aβ40. The obvious 
next step is to confirm the Aβ profile in vivo, including measurement of other Aβ species, 
perhaps by lentiviral-mediated delivery of APP constructs into rodent brain. From there, 
it would be interesting to determine whether expression of APP5R could prevent 
pathology in a transgenic FAD mouse model, and up to what stage of pathogenesis it is 
effective. These questions are important to understanding the possible effects of γ-
secretase modulators. They also open the possibility that upregulating APP 
ubiquitination, for instance with a deubiquitinase inhibitor, could be pursued as a 
therapeutic intervention in AD.  
We sought to understand the ubiquitin-dependent endosomal pathways that dictate APP 
trafficking and thus its processing. Our findings suggest that ubiquitin is indeed an 
important signal for efficient sorting of APP in ILVs and the absence of APP/CTFs in 
ILVs corresponds to decreased exosomal content. The missorted APP that accumulates 
on the endosomal membrane is cleaved by PSEN2, as suggested by recent data regarding 
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differential localization of PSEN1 and PSEN2 (see Chapter 4). It will be important in the 
future to determine the molecular mechanisms underlying exosome biogenesis and the 
switches that can dictate cargo loading and fate of ILVs, especially as growing evidence 
suggests that exosomes are important players in pathogenesis of neurodegenerative 
disease. Equally important will be the study of contribution of different γ-secretase 
subunits to the localization and specificity of the entire complex. We hope that our 
findings will add to the current knowledge of endosomal sorting of APP, open up new 
avenues for discovery of new therapeutic targets, and perhaps provide tools that will help 
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